

PCT

SCIENCE REFERENCE AND INFORMATION SERVICE
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



HB

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :

C12Q 1/68, A61K 31/70
C07H 17/00

A1

(11) International Publication Number:

WO 92/20823

(43) International Publication Date:

26 November 1992 (26.11.92)

(21) International Application Number: PCT/US92/04305

(22) International Filing Date: 21 May 1992 (21.05.92)

(30) Priority data:
703,619 21 May 1991 (21.05.91) US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

703,619 (CIP)

21 May 1991 (21.05.91)

(71) Applicants (for all designated States except US): ISIS
PHARMACEUTICALS, INC. [US/US]; 2280 Faraday
Avenue, Carlsbad, CA 92009 (US). CIBA-GEIGY AG
[CH/CH]; P.O. Box R-1060.2.44, CH-4002 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DE MESMAEKER,
Alain [BE/CH]; Ueligasse 31, CH-4447 Kaerkerkinden
(CH). LEBRETON, Jacques [FR/FR]; 27, rue de Nor-
dfeld, F-68100 Mulhouse (FR). WALDNER, Adrian
[CH/CH]; Holeeweg 32, CH-4123 Basel (CH). COOK,
Phillip, Dan [US/US]; 7340 Bolero Street, Carlsbad, CA
92009 (US).

(74) Agents: CALDWELL, John, W. et al.; Woodcock Wash-
burn Kurtz Mackiewicz & Norris, One Liberty Place -
46th Floor, Philadelphia, PA 19103 (US).

(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), BR, CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European
patent), FI, FR (European patent), GB (European pa-
tent), GR (European patent), HU, IT (European patent),
JP, KR, LU (European patent), MC (European patent),
NL (European patent), NO, SE (European patent), US.

Published

With international search report.

With amended claims and statement.

Date of publication of the amended claims and statement:

21 January 1993 (21.01.93)

AMENDED
SPECIFICATION
ORIGINAL
FILED BEHIND

(54) Title: BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS

(57) Abstract

Therapeutic oligonucleotide analogs which have improved nuclease resistance and improved cellular uptake are provided. Replacement of phosphodiester inter-sugar linkages found in wild type oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | FI | Finland | MI | Mali |
| AU | Australia | FR | France | MN | Mongolia |
| BB | Barbados | GA | Gabon | MR | Mauritania |
| BE | Belgium | GB | United Kingdom | MW | Malawi |
| BF | Burkina Faso | GN | Guinea | NI | Netherlands |
| BG | Bulgaria | GR | Greece | NO | Norway |
| BJ | Benin | HU | Hungary | PL | Poland |
| BR | Brazil | IE | Ireland | RO | Romania |
| CA | Canada | IT | Italy | RU | Russian Federation |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | KR | Republic of Korea | SN | Senegal |
| CI | Côte d'Ivoire | LI | Liechtenstein | SU | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| CS | Czechoslovakia | LU | Luxembourg | TG | Togo |
| DE | Germany | MC | Monaco | US | United States of America |
| DK | Denmark | MG | Madagascar | | |
| ES | Spain | | | | |

PCT

SCIENTIFIC AND INFORMATION SERVICE

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|----|---|
| (51) International Patent Classification ⁵ : C12Q 1/68, A61K 31/70 C07H 17/00 | A1 | (11) International Publication Number: WO 92/20823 (43) International Publication Date: 26 November 1992 (26.11.92) |
|--|----|---|

(21) International Application Number: PCT/US92/04305
(22) International Filing Date: 21 May 1992 (21.05.92)
(30) Priority data:
703,619 21 May 1991 (21.05.91) US

(60) Parent Application or Grant
(63) Related by Continuation
US 703,619 (CIP)
Filed on 21 May 1991 (21.05.91)

(71) Applicants (for all designated States except US): ISIS
PHARMACEUTICALS, INC. [US/US]; 2280 Faraday
Avenue, Carlsbad, CA 92009 (US); CIBA-GEIGY AG
[CH/CH]; P.O. Box R-1060.2.44, CH-4002 Basel (CH).

SEE AMENDED
SPECIFICATION
FILED IN FRONT

(72) Inventors; and
(75) Inventors/Applicants (for US only): DE MESMAEKER,
Alain [BE/CH]; Ueligasse 31, CH-4447 Kaenerkinden
(CH). LEBRETON, Jacques [FR/FR]; 27, rue de Nor-
dfeld, F-68100 Mulhouse (FR). WALDNER, Adrian
[CH/CH]; Holeeweg 32, CH-4123 Basel (CH). COOK,
Phillip, Dan [US/US]; 7340 Bolero Street, Carlsbad, CA
92009 (US).

(74) Agents: CALDWELL, John, W. et al.; Woodcock Wash-
burn Kurtz Mackiewicz & Norris, One Liberty Place -
46th Floor, Philadelphia, PA 19103 (US).

(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), BR, CA, CH (European patent), DE (Eu-
ropean patent), DK (European patent), ES (European
patent), FI, FR (European patent), GB (European pa-
tent), GR (European patent), HU, IT (European patent),
JP, KR, LU (European patent), MC (European patent),
NL (European patent), NO, SE (European patent), US.

Published
With international search report.

(54) Title: BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS

(57) Abstract

Therapeutic oligonucleotide analogs which have improved nuclease resistance and improved cellular uptake are provided. Replacement of phosphodiester inter-sugar linkages found in wild type oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | FI | Finland | MI | Mali |
| AU | Australia | FR | France | MN | Mongolia |
| BB | Barbados | GA | Gabon | MR | Mauritania |
| BE | Belgium | GB | United Kingdom | MW | Malawi |
| BF | Burkina Faso | GN | Guinea | NL | Netherlands |
| BG | Bulgaria | GR | Greece | NO | Norway |
| BJ | Benin | HU | Hungary | PL | Poland |
| BR | Brazil | IE | Ireland | RO | Romania |
| CA | Canada | IT | Italy | RU | Russian Federation |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | KR | Republic of Korea | SN | Senegal |
| CI | Côte d'Ivoire | LI | Liechtenstein | SU | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| CS | Czechoslovakia | LU | Luxembourg | TC | Togo |
| DE | Germany | MC | Monaco | US | United States of America |
| DK | Denmark | MG | Madagascar | | |
| ES | Spain | | | | |

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12Q 1/68; A61K 31/70; C07H 17/00

US CL : 435/6; 514/44; 536/23,27,28,29,124

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 514/44; 536/23,27,28,29,124

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| Y | Cohen, ed., "Non-ionic Antisense Oligonucleotides" in <u>Oligonucleotides</u> , published 1989, by CRC Press, Inc. (USA), see pages 79 and 80. | 1-19 |
| Y | John Goodchild, "Inhibition of Gene Expression by Oligonucleotides" in <u>Oligonucleotides</u> , published 1989, by CRC Press Inc., (USA), see pages 53-78. | 20-21 |
| Y | Tetrahedron Letters, Volume 31, Number 17, issued 22 May 1990 (London), Mark Matteucci, "Deoxyoligonucleotide Analogs Based on Formacetal Linkages", see pages 2385-2388. | 20-21 |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

| | | |
|--|------|--|
| * Special categories of cited documents: | * T | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| * A* document defining the general state of the art which is not considered to be part of particular relevance | * X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| * E* earlier document published on or after the international filing date | * Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| * L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | * A* | document member of the same patent family |
| * O* document referring to an oral disclosure, use, exhibition or other means | | |
| * P* document published prior to the international filing date but later than the priority date claimed | | |

| | |
|---|---|
| Date of the actual completion of the international search 13 AUGUST 1992 | Date of mailing of the international search report 03 SEP 1992 |
| Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE | Authorized officer JAMES O. WILSON Telephone No. (703) 308-0196 |

BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Application Serial No. 703,619, filed May 21, 1991, which is a continuation-in-part of U.S. Application Serial No. 566,836, filed August 13, 1990, and U.S. Serial No. 558,663, filed July 27, 1990. Each of these applications is incorporated herein by reference.

FIELD OF THE INVENTION

10 This invention relates to the design, synthesis and application of nuclease resistant oligonucleotide analogs which are useful for therapeutics, diagnostics and as research reagents. The oligonucleotide analogs of the invention have modified linkages instead of the
15 phosphorodiester bonds that normally serve as inter-sugar linkages in wild type nucleic acids. The analogs of the invention are resistant to nuclease degradation and are capable of modulating the activity of DNA and RNA. Methods for synthesizing these oligonucleotide analogs and for
20 modulating the production of proteins using the oligonucleotide analogs of the invention are also provided.

- 2 -

BACKGROUND OF THE INVENTION

It is well known that most of the bodily states in mammals, including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man.

Classical therapeutics has generally focused upon interactions with such proteins in an effort to moderate their disease causing or disease potentiating functions. Recently, however, attempts have been made to moderate the actual production of such proteins by interactions with the molecules (i.e., intracellular RNA) that direct their synthesis. These interactions have involved the hybridization to RNA of complementary "antisense" oligonucleotides or certain analogs thereof. Hybridization is the sequence-specific hydrogen bonding of oligonucleotides or oligonucleotide analogs to RNA or to single stranded DNA. By interfering with the production of proteins, it has been hoped to effect therapeutic results with maximum effect and minimal side effects. Oligonucleotide analogs also may modulate the production of proteins by an organism by a similar mechanism.

The pharmacological activity of antisense oligonucleotides and oligonucleotide analogs, like other therapeutics, depends on a number of factors that influence the effective concentration of these agents at specific intracellular targets. One important factor for oligonucleotides is the stability of the species in the presence of nucleases. It is unlikely that unmodified oligonucleotides will be useful therapeutic agents because they are rapidly degraded by nucleases. Modifications of oligonucleotides to render them resistant to nucleases therefore are greatly desired.

Modifications of oligonucleotides to enhance nuclease resistance have generally taken place on the phosphorus atom of the sugar-phosphate backbone. Phosphorothioates, methyl phosphonates, phosphoramidates,

- 3 -

and phosphorotriesters have been reported to confer various levels of nuclease resistance. However, phosphate-modified oligonucleotides of this type generally have suffered from inferior hybridization properties. Cohen, J.S., ed.

- 5 *Oligonucleotides: Antisense Inhibitors of Gene Expression*, (CRC Press, Inc., Boca Raton FL, 1989).

Another key factor is the ability of antisense compounds to traverse the plasma membrane of specific cells involved in the disease process. Cellular membranes
10 consist of lipid-protein bilayers that are freely permeable to small, nonionic, lipophilic compounds yet inherently impermeable to most natural metabolites and therapeutic agents. Wilson, D.B. *Ann. Rev. Biochem.* 47:933-965 (1978). The biological and antiviral effects of natural and
15 modified oligonucleotides in cultured mammalian cells have been well documented. Thus, it appears that these agents can penetrate membranes to reach their intracellular targets. Uptake of antisense compounds by a variety of mammalian cells, including HL-60, Syrian Hamster
20 fibroblast, U937, L929, CV-1 and ATH8 cells, has been studied using natural oligonucleotides and certain nuclease resistant analogs, such as alkyl triesters. Miller, P.S., Braiterman, L.T. and Ts'O, P.O.P., *Biochemistry* 16:1988-1996 (1977); methyl phosphonates, Marcus-Sekura, C.H.,
25 Woerner, A.M., Shinozuka, K., Zon, G., and Quinman, G.V., *Nuc. Acids Res.* 15:5749-5763 (1987) and Miller, P.S., McParland, K.B., Hayerman, K. and Ts'O, P.O.P., *Biochemistry* 16: 1988-1996 (1977) and Loke, S.K., Stein, C., Zhang, X.H. Avigan, M., Cohen, J. and Neckers, L.M.
30 *Top. Microbiol. Immunol.* 141: 282:289 (1988).

Modified oligonucleotides and oligonucleotide analogs often are less readily internalized than their natural counterparts. As a result, the activity of many previously available antisense oligonucleotides has not
35 been sufficient for practical therapeutic, research or diagnostic purposes. Two other serious deficiencies of prior art oligonucleotides that have been designed for

- 4 -

antisense therapeutics are inferior hybridization to intracellular RNA and the lack of a defined chemical or enzyme-mediated event to terminate essential RNA functions.

Modifications to enhance the effectiveness of the antisense oligonucleotides and overcome these problems have taken many forms. These modifications include base ring modifications, sugar moiety modifications, and sugar-phosphate backbone modifications. Prior sugar-phosphate backbone modifications, particularly on the phosphorus atom, have effected various levels of resistance to nucleases. However, while the ability of an antisense oligonucleotide to bind to specific DNA or RNA with fidelity is fundamental to antisense methodology, modified phosphorus oligonucleotides have generally suffered from inferior hybridization properties.

Replacement of the phosphorus atom has been an alternative approach in attempting to avoid the problems associated with modification on the pro-chiral phosphate moiety. Some modifications in which replacement of the phosphorus atom has been achieved are disclosed by: Matteucci, M. *Tetrahedron Letters* 31:2385-2388 (1990), wherein replacement of the phosphorus atom with a methylene group is limited by available methodology which does not provide for uniform insertion of the formacetal linkage throughout the backbone, and its instability, making it unsuitable for work; Cormier, et al. *Nucleic Acids Research* 16:4583-4594 (1988), wherein replacement of the phosphorus moiety with a diisopropylsilyl moiety is limited by methodology, solubility of the homopolymers and hybridization properties; Stirchak, et al. *Journal of Organic Chemistry* 52:4202-4206 (1987), wherein replacement of the phosphorus linkage by short homopolymers containing carbamate or morpholino linkages is limited by methodology, the solubility of the resulting molecule, and hybridization properties; Mazur, et al. *Tetrahedron* 40:3949-3956 (1984), wherein replacement of the phosphorus linkage with a phosphonic linkage has not been developed beyond the

- 5 -

synthesis of a homotrimer molecule; and Goodchild, J., *Bioconjugate Chemistry* 1:165-187 (1990), wherein ester linkages are enzymatically degraded by esterases and are therefore unsuitable to replace the phosphate bond in antisense applications.

The limitations of the available methods for modification of the phosphorus backbone have led to a continuing and long felt need for other modifications which provide resistance to nucleases and satisfactory hybridization properties for antisense oligonucleotide diagnostics, therapeutics, and research.

OBJECTS OF THE INVENTION

It is an object of the invention to provide oligonucleotide analogs for use in antisense oligonucleotide diagnostics, research reagents, and therapeutics.

It is a further object of the invention to provide oligonucleotide analogs which possess enhanced cellular uptake.

Another object of the invention is to provide such oligonucleotide analogs which have greater efficacy than unmodified antisense oligonucleotides.

It is yet another object of the invention to provide methods for synthesis and use of such oligonucleotide analogs.

These and other objects will become apparent to persons of ordinary skill in the art from a review of the present specification and the appended claims.

SUMMARY OF THE INVENTION

Compositions useful for modulating the activity of an RNA or DNA molecule in accordance with this invention generally comprise oligonucleotide analogs having at least portions of their backbone linkages modified. In these modifications, the phosphorodiester linkage of the sugar phosphate backbone found in wild type nucleic acids has

- 6 -

been replaced with various four atom linking groups. Such four atom linking groups maintain a desired four atom spacing between the 3'-carbon of one sugar or sugar analog and the 4'-carbon of the adjacent sugar or sugar analog.

5 Oligonucleotide analogs made in accordance with the teachings of the invention are comprised of a selected sequence which is specifically hybridizable with a preselected nucleotide sequence of single stranded or double stranded DNA or RNA. They are synthesized through, 10 for example, known solid state synthetic methodology to be complementary to or at least to be specifically hybridizable with the preselected nucleotide sequence of the RNA or DNA. Nucleic acid synthesizers are commercially available and their use is generally understood by persons 15 of ordinary skill in the art as being effective in generating nearly any oligonucleotide or oligonucleotide analog of reasonable length which may be desired.

In the context of this invention, the term "nucleoside" refers to the unit made up of a heterocyclic 20 base and its sugar. The term "nucleotide" refers to a nucleoside having a phosphate group on its 3' or 5' sugar hydroxyl group. Thus, nucleosides, unlike nucleotides, have no phosphate group. "Oligonucleotide" refers to a plurality of joined nucleotide units formed in a specific 25 sequence from naturally occurring bases and pentofuranosyl groups joined through a sugar group by native phosphodiester bonds. These nucleotide units may be nucleic acid bases such as guanine, adenine, cytosine, thymine or uracil. The sugar group can be a deoxyribose or 30 ribose. This term refers to both naturally occurring and synthetic species formed from naturally occurring subunits.

The term "oligonucleotide analog", as used in connection with this invention, refers to moieties which function similarly to oligonucleotides but which have non- 35 naturally occurring portions. Oligonucleotide analogs can have altered sugar moieties, altered base moieties or altered inter-sugar linkages. For the purposes of this

- 7 -

invention, an oligonucleotide analog having non-phosphodiester bonds, i.e., an altered inter-sugar linkage, can alternately be considered as an "oligonucleoside."


Such an oligonucleoside thus refers to a plurality of
5 joined nucleoside units joined by linking groups other than native phosphodiester linking groups. Additionally, for the purposes of this invention, the terminology "oligomers" can be considered to encompass oligonucleotides, oligonucleotide analogs or oligonucleosides. Thus, in
10 speaking of "oligomers" reference is made to a series of nucleosides or nucleoside analogs that are joined together via either natural phosphodiester bonds or via other linkages including the four atom linkers of this invention. Generally, while the linkage is from the 3' carbon of one
15 nucleoside to the 5' carbon of a second nucleoside, the term "oligomer" can also include other linkages such as a 2' - 5' linkage.

Oligonucleotide analogs can also comprise other modifications consistent with the spirit of this invention, particularly that increase nuclease resistance and, thus,
20 facilitate antisense therapeutic, diagnostic, or research reagent use of a particular oligonucleotide. For example, when the sugar portion of a nucleoside or nucleotide is replaced by a carbocyclic or other moiety, it is no longer a sugar. Moreover, when other substitutions, such a
25 substitution for the inter-sugar phosphodiester linkage are made, the resulting material is no longer a true nucleic acid species. The compounds that result from such substitutions all are denominated as analogs. Throughout
30 this specification, reference to the sugar portion of a nucleic acid species shall be understood to refer to either a true sugar or to a species taking the traditional space of the sugar of wild type nucleic acids. Moreover, reference to inter-sugar linkages shall be taken to include
35 moieties serving to join the sugar or sugar analog portions together in the fashion of wild type nucleic acids.

- 8 -

In accordance with the present invention, novel types of antisense oligonucleotide analogs and oligonucleosides are provided which are modified to enhance cellular uptake, nuclease resistance, and hybridization properties and to provide a defined chemical or enzymatically mediated event to terminate essential RNA functions.

It has been found that certain classes of oligonucleotide analog compositions can be useful in therapeutics and for other objects of this invention. Such oligonucleotide analogs are formed from subunits, at least some of which have the structure:



wherein B_x is a variable base moiety; Q is O, CH_2 , CHF or CF_2 and X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino or substituted silyl. Moreover, X can be an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide.

L_1 and L_4 are, independently, CH_2 , C=O, C=S, C-NH $_2$, C-NHR $_3$, C-OH, C-SH, C-O-R $_1$ or C-S-R $_1$. L_2 and L_3 are,

- 9 -

independently, CR_1R_2 , $C=CR_1R_2$, $C=NR_3$, $P(O)R_4$, $P(S)R_4$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_5R_6 ; or, together, form part of an alkene, alkyne, aromatic ring, carbocycle or heterocycle. L_1 , L_2 , L_3 and L_4 , together, can comprise a -

5 $CH=N-NH-CH_2-$ or $-CH_2-O-N=CH-$ moiety.

R_1 and R_2 are, independently, H ; OH ; SH ; NH_2 ; C_1 to C_{10} alkyl, substituted alkyl, alkenyl, alkaryl or aralkyl; alkoxy; thioalkoxy; alkylamino; aralkylamino; substituted alkylamino; heterocycloalkyl; heterocycloalkylamino; aminoalkylamino; polyalkylamino; halo; formyl; keto; benzoxy; carboxamido; thiocarboxamido; ester; thioester; carboxamidine; carbamyl; ureido or guanidino. They can also independently comprise an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;

R_3 is H , OH , NH_2 , lower alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, an RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic properties of an oligonucleotide. R_4 is OH , SH , NH_2 , O -alkyl, S -alkyl, NH -alkyl, O -alkylheterocyclo, S -alkylheterocyclo, N -alkylheterocyclo or a nitrogen-containing heterocycle.


R_5 and R_6 are, independently, C_1 to C_6 alkyl or alkoxy; provided that if L_2 is $P(O)R_4$ and R_4 is OH and X is OH and B_x is uracil or adenine, then L_3 is not O ; and that if L_1 , L_2 and L_4 are CH_2 and X is H or OH and Q is O then L_3 is not S , SO or SO_2 .

In accordance with preferred embodiments, the oligonucleotide analogs of the invention comprise sugar moieties, such that Q is O . In accordance with other embodiments, each of L_1 and L_4 are either CR_1R_2 or $C=O$, preferably CR_1R_2 . It is also preferred that L_2 and L_3 be, independently, CR_1R_2 , O , $P(O)R_4$, $P(S)R_4$ or NR_3 and especially

- 10 -

that one of L_2 and L_3 be CR_1R_2 and the other of L_2 and L_3 be $P(O)R_4$ or $P(S)R_4$. Combinations where L_2 is O and L_3 is $P(O)R_4$ or $P(S)R_4$ are also preferred.

In accordance with other embodiments, the
 5 oligonucleotide analogs of this invention are such that each of L_2 and L_3 is NR_3 where R_3 is preferably H. More preferably, the oligonucleotide analogs have one of the following formulas:



Alternatively, the analogs of the invention can
 10 be such that L_2 and L_3 taken together, form a portion of a cyclopropyl, cyclobutyl, ethyleneoxy, ethyl aziridine or substituted ethyl aziridine ring. L_2 and L_3 taken together can also form a portion of a C_3 to C_6 carbocycle or 4-, 5- or
 35 6-membered nitrogen heterocycle.

- 11 -

Thus, $L_1-L_2-L_3-L_4$ can be selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is

5 hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving the affinity for the RNA complement or a group for improving the pharmacodynamic properties of the

10 oligonucleotide. The remaining subunits of the oligonucleotides are natural or synthetic subunits as will be appreciated by persons of ordinary skill in the art.

It is preferred that the oligonucleotide analogs be such that X is H or OH, or, alternatively F, O-alkyl or

15 O-alkenyl, especially where Q is O. The group B_x is preferably adenine, guanine, uracil, thymine, cytosine, 2-aminoadenosine or 5-methylcytosine, although other non-naturally occurring species can be employed.

Other preferred embodiments are those where L_1 and

20 L_4 are each CH_2 , especially where L_2 and L_3 are each NH. Alternatively, one of L_2 and L_3 , preferably, L_3 , is O and the other of L_2 and L_3 is NH.

It is preferred that the oligonucleotide analogs of the invention comprise from about 4 to about 50

25 subunits, and even more preferably from about 5 to about 20 subunits having the given structure. While substantially each subunit of the oligonucleotide analogs can have said structure, it is also desirable for substantially alternating subunits to have said structure.

30 The oligonucleotide analogs of this invention are preferably prepared in a pharmaceutically acceptable carrier for therapeutic administration to patients. The analogs are believed to exhibit improved nuclease resistance as compared to corresponding wild type oligo-


35 nucleotides. This invention is also directed to methods for modulating the production or activity of a protein in an organism comprising contacting the organism with an

- 12 -

oligonucleotide analog specifically hybridizable with at least a portion of a nucleic acid sequence coding for said protein, wherein at least some of the subunits of the analog have the foregoing structure.

5 Additionally, the invention is directed to methods for treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligonucleotide analog hybridizable with at least a portion of a nucleic
10 acid sequence coding for said protein, either alone or in a pharmaceutically acceptable carrier, wherein at least some of the subunits of the analog have the given structure.


 In another aspect, the present invention provides compounds useful in preparing the above-described
15 oligonucleotide analogs. In certain embodiments, these compounds have a structure:




wherein R_{HP1} and R_{HP2} are, independently, H or hydroxyl protecting groups. In certain embodiments, these compounds

- 13 -

are prepared by providing a first synthon having structure (I) and second synthon having structure (II):



(I)



(II)


5 wherein:

- (a) R_T is NH_2 and R_B is $R_A\text{-CH}_2\text{-CH}_2$;
- (b) R_T is $\text{CH}_2\text{-NH}_2$ and R_B is $R_A\text{-CH}_2$;
- (c) R_T is $\text{CH}_2\text{-CH}_2\text{-NH}_2$ and R_B is R_A ;
- (d) R_T is R_A and R_B is $\text{NH}_2\text{-CH}_2\text{-CH}_2$; or
- 10 (e) R_T is $\text{CH}_2\text{-R}_A$ and R_B is $\text{NH}_2\text{-CH}_2$;


where R_A is C(O)OH , C(S)OH , or an activated derivative thereof; and

coupling the first and second synthons to form an amide or thioamide linkage through the R_T and R_B groups.

15 This invention also provides methods for synthesizing oligonucleotide analogs, including those useful in the practice of the therapeutic methods of the invention. Certain of these methods comprise providing a first moiety comprising the structure:



20 and a second moiety comprising the structure:



wherein B_x is a variable base moiety; Q is O , CH_2 , CHF or CF_2 ; and E_1 and E_2 are the same or different and are

- 14 -

electrophilic reactive groups; and coupling said first and second moieties with a linking group through said electrophilic reactive groups to form said oligonucleotide analog. In accordance with preferred methods, the

5 electrophilic reactive group of the first moiety comprises halomethyl, trifluoromethyl, sulfonylmethyl, p-methyl-benzene sulfonyl-methyl, or 3'-C-formyl, while the electrophilic reactive group of the second moiety comprises


10 halogen, sulfonylmethyl, p-methyl-benzene sulfonyl methyl, or aldehyde. It is preferred that the linking group be hydrazine or hydroxylamine.

It is useful to formulate therapeutic compositions where at least one portion of said oligonucleotide analog is incorporated into a further

15 oligonucleotide species to provide said further oligonucleotide analog with wild type phosphodiester bonds substantially alternating with areas so coupled. The incorporation is preferably achieved by phosphodiester linkage of a desired sequence of dinucleotides, said

20 dinucleotides having been previously so coupled.

Precursor nucleosides are also contemplated by this invention having the structure:



wherein B_x is a variable base moiety Q is O, CH_2 , CHF or CF_2 ; and X is H; OH; C_1 to C_{10} lower alkyl, substituted lower

25 alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA

30 cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide.

- 15 -

In such species, Y is hydroxyl, aminomethyl, hydrazinomethyl, hydroxymethyl, C-formyl, phthalimido-hydroxymethyl, aryl-substituted imidazolidino, amino-hydroxylmethyl, ortho-methylaminobenzenethio, methyl-phosphonate and methylalkylphosphonate. Z is H, hydroxyl, aminomethyl, hydrazinomethyl, hydroxymethyl, C-formyl, phthalimidohydroxymethyl, aryl substituted imidazolidino, aminohydroxylmethyl, ortho-methylaminobenzenethio, methyl-phosphonate or methyl alkylphosphonate. All of the foregoing is with the proviso that when Q is O and Y is hydroxymethyl and X is H or OH then Z is not C-formyl; and that when Q is O and X is H or OH and Z is hydroxyl then Y is not aminohydroxylmethyl, hydrazinomethyl or aryl substituted imidazolidino. It is preferred that X be H or OH and that Q be O.

Oligonucleotide analogs having modified sugar linkages have been found to be effective in accomplishing these goals. The oligonucleotide analogs preferably range from about 4 to about 50 nucleic acid base subunits in length, with from about 5 to about 20 being more preferred. Oligonucleotide analogs described in this invention are hybridizable with preselected nucleotide sequences of single stranded or double stranded DNA and RNA. The nucleic acid bases which comprise this invention can be pyrimidines such as thymine, uracil or cytosine or purines such as guanine or adenine, or modifications thereof such as 5-methylcytosine, arranged in a selected sequence. The sugar moiety can be of the ribose or deoxyribose type or a sugar mimic such as a carbocyclic ring. In accordance with one preferred embodiment of this invention, the oligonucleotide analogs or oligonucleosides hybridize to HIV mRNA encoding the tat protein, or to the TAR region of HIV mRNA. The oligonucleotide analogs or oligonucleosides can mimic the secondary structure of the TAR region of HIV mRNA to bind the tat protein. Other preferred antisense oligonucleotide analog or oligonucleoside sequences include

- 16 -

complementary sequences for herpes, papilloma and other viruses.

The modified linkages of this invention preferably use a four atom linking group to replace the naturally occurring phosphodiester-5'-methylene linkage. Replacement of the naturally occurring linkage by four atom linkers of the present invention confers nuclease resistance and enhanced cellular uptake upon the resulting oligonucleotide analog. Preferably included within the four atom linker is a 3'-deoxy function on one of the linked sugars. The four atom linker is of the structure $-L_1-L_2-L_3-L_4-$ wherein L_1 and L_4 are methylene carbon atoms or substituted carbon atoms and L_2 and L_3 are methylene carbon atoms, substituted carbon atoms, oxygen atoms, nitrogen or substituted nitrogen atoms, substituted phosphorus atoms, sulfur or substituted sulfur atoms or substituted silicon atoms. It is preferred that the modified linkage occur at substantially each linkage location. Alternatively, modification can occur at less than every location such as at alternating linkage locations or substantially randomly. The linkage can be neutral or can be positively or negatively charged.

This invention is also directed to methods for synthesizing such oligonucleosides. The invention provides for the coupling of a 3'-deoxy-3'-substituted, especially methyl substituted, nucleoside with a 5'-deoxy-5'-substituted nucleoside through the addition of a two atom fragment or substituted two atom fragment. The addition reaction can occur through a stepwise procedure involving the activation of the 3' and 5' positions of respective nucleosides to a variety of suitable electrophilic moieties, followed by the addition of a suitable linking group to react with the electrophiles. In the alternative, the procedure can occur in a concerted manner. Such methods can employ solid supports via a DNA synthesizer, by manual manipulation of the support, or otherwise.

This invention is also directed to methods for modulating the production of proteins by an organism comprising contacting the organism with a composition formulated in accordance with the foregoing considerations.

- 5 It is preferred that the RNA or DNA portion which is to be modulated be preselected to comprise that portion of DNA or RNA which codes for the protein whose formation or activity is to be modulated. The targeting portion of the composition to be employed is, thus, selected to be
10 complementary to the preselected portion of DNA or RNA, that is to be an antisense oligonucleotide for that portion.

- This invention is also directed to methods for treating an organism having a disease characterized by the
15 undesired production of a protein. This method comprises contacting the organism with a composition in accordance with the foregoing considerations. The composition is preferably one which is designed to specifically bind with messenger RNA which codes for the protein whose production
20 or activity is to be modulated. The invention further is directed to diagnostic methods for detecting the presence or absence of abnormal RNA molecules or abnormal or inappropriate expression of normal RNA molecules in organisms or cells.

- 25 This invention is also directed to methods for the selective binding of RNA for research and diagnostic purposes. Such selective, strong binding is accomplished by interacting such RNA or DNA with compositions of the invention which are resistant to degradative nucleases and
30 which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs.

- 18 -

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic, synthetic scheme in accordance with certain embodiments of the invention; and


Figure 2 is a schematic, synthetic scheme in accordance with further embodiments of the invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The biological activity of the antisense oligonucleotides previously available has not generally been sufficient for practical therapeutic research or diagnostic use. This invention is directed to modified oligonucleotides, i.e. oligonucleotide analogs or oligonucleosides, and to methods for effecting useful modifications. These modified oligonucleotides and oligonucleotide analogs exhibit increased stability relative to their naturally occurring counterparts. Extracellular and intracellular nucleases generally do not recognize and, therefore, do not bind to the backbone modified oligonucleotide analogs or oligonucleosides of the present invention. Any binding by a nuclease to the backbone will not result in cleavage of the nucleosidic linkages due to the lack of sensitive, phosphorus-oxygen bonds. In addition, the resulting, novel neutral or positively charged backbones of the present invention can be taken into cells by simple passive transport rather than requiring complicated protein mediated processes. Another advantage of the present invention is that the lack of a negatively charged backbone facilitates the sequence specific binding of the oligonucleotide analogs or oligonucleosides to targeted RNA, which has a negatively charged backbone, and which will accordingly repel incoming similarly charged oligonucleotides. Still another advantage of the present invention is that sites for attaching functional groups which can initiate catalytic cleavage of targeted RNA are found in these structure types.

- 19 -

In accordance with preferred embodiments, this invention is directed to replacing inter-sugar phosphate groups to yield oligonucleotides having linkages as found in the structure:



5 wherein

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;

- X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ;
 10 OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$;
 SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl;
 heterocycloalkaryl; aminoalkylamino; polyalkylamino;
 substituted silyl; an RNA cleaving group; a group for
 improving the pharmacokinetic properties of an
 15 oligonucleotide; or a group for improving the
 pharmacodynamic properties of an oligonucleotide;

L_1 and L_4 are, independently, CH_2 , C=O, C=S, C-NH $_2$, C-NHR $_3$, C-OH, C-SH, C-O-R $_1$ or C-S-R $_1$; and

- L_2 and L_3 are, independently, CR $_1$ R $_2$, C=CR $_1$ R $_2$, C=NR $_3$,
 20 P(O)R $_4$, P(S)R $_4$, C=O, C=S, O, S, SO, SO_2 , NR $_3$ or SiR $_5$ R $_6$; or,
 together, form part of an alkene, alkyne, aromatic ring,
 carbocycle or heterocycle;

L_1 , L_2 , L_3 and L_4 , together, comprise a -CH=N-NH-CH $_2$ - or -CH $_2$ -O-N=CH- moiety; or

- 20 -

$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving the affinity for the RNA complement or a group for improving the pharmacodynamic properties of the oligonucleotide;

10 R_1 and R_2 are, independently, H; OH; SH; NH_2 ; C_1 to C_{10} alkyl, substituted alkyl, alkenyl, alkaryl or aralkyl; alkoxy; thioalkoxy; alkylamino; aralkylamino; substituted alkylamino; heterocycloalkyl; heterocycloalkylamino; aminoalkylamino; polyalkylamino; halo; formyl; keto; 1
15 benzoxy; carboxamido; thiocarboxamido; ester; thioester; carboxamidine; carbamyl; ureido; guanidino; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide; 1

20 R_3 is H, OH, NH_2 , lower alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocyclocalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, an RNA cleaving group, a group for improving the 2
25 pharmacokinetic properties of an oligonucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; 2

R_4 is OH, SH, NH_2 , O-alkyl, S-alkyl, NH-alkyl, O-alkylheterocycle, S-alkylheterocycle, N-alkylheterocycle or 3
30 a nitrogen-containing heterocycle; and 3

R_5 and R_6 are, independently, C_1 to C_6 alkyl or alkoxy; 3
provided that if L_2 is $P(O)R_4$ and R_4 is OH and X is OH and B_x is uracil or adenine, then L_3 is not O; and that if L_1 , L_2 and L_4 are CH_2 and X is H or OH and Q is O then L_3 is not S, 35
SO or SO_2 .

- 21 -

In accordance with preferred embodiments of the invention L_1 and L_4 are methylene groups. In such preferred embodiments one of L_2 or L_3 can comprise an amino group and the other comprise an amino group or an oxygen. Thus, in
5 certain preferred embodiments L_2 and L_3 together are hydrazino, aminohydroxy or hydroxyamino. In other preferred embodiments one of L_1 or L_4 together with one of L_2 or L_3 are a $CH=N$ group and the other of L_2 or L_3 is an oxygen or nitrogen atom thus the linker includes oxime and
10 hydrazone groupings, respectively. Such oxime or hydrazone linking groups can be reduced to the above referenced aminohydroxy or hydrazine groups.

In other preferred embodiments, the $L_1-L_2-L_3-L_4$ series contains a N-substituted or N-unsubstituted amide or
15 thioamide functionality.

In still other preferred embodiments of the present invention, L_2 and L_3 are substituted carbon, amino, substituted amine, oxygen, sulfur, oxides of sulfur, phosphorus or silicon. The substituents on carbon include
20 hydrogen, hydroxy, thio, amino, lower alkyl, substituted lower alkyl, alkoxy, thioalkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, halogen, formyl, keto, benzoxy,
25 carboxamido, thiocarboxamido, ester, thioester, carboxamidine, carbamyl, ureido, guanidino, an RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic properties of an oligonucleotide.
30 Additional preferred embodiments include L_2 and L_3 together being $C=C$. Further preferred embodiments include L_2 and L_3 together being a $C-C$, $C=C$, $C-N$ or $N-C$ two atom pair of a ring structure including carbocyclic, aromatic, heteroaromatic or heterocyclic rings. Still another
35 preferred embodiment of the present invention provides that L_1 and L_4 independently are carboxy, thiocarboxy, methylamino, methylhydroxy, methylthio, ether or thioether.

- 22 -


The invention is also directed to methods for the preparation of oligonucleosides with modified inter-sugar linkages. These modifications can be effected using solid supports which can be manually manipulated or used in conjunction with a DNA synthesizer using methodology commonly known to those skilled in DNA synthesizer arts. Generally, the procedure involves functionalizing the sugar moieties of two nucleosides which will be adjacent to one another in the selected sequence. In a 5' to 3' sense, the "upstream" nucleoside is generally modified at the 3' sugar site and is referred to hereinafter as "synthon 1". In one process of the invention, ribo- and 2'-deoxyribonucleosides of adenine, guanine, cytosine, uracil, thymine and their analogs are modified to give their 3'-deoxy-3-hydroxymethyl analogs. These 3'-hydroxymethyl groups are then converted into various types of electrophilic centers. This can be accomplished in a number of ways such as the following, preferred scheme.

One class of starting materials, 3'-deoxy-3'-hydroxymethyl ribonucleosides, can be prepared as described by Townsend et al., *Tetrahedron Letters*, 31:3101-3104 (1990), Samano, V. and M.J. Morris, *Journal of Organic Chemistry*, 55:5186-5188 (1990) and Bergstrom, D.E., *Nucleosides and Nucleotides* 8(8): 1529-1535 (1989). Appropriate, known, selective sugar hydroxyl protection of these nucleosides followed by standard 2'-deoxygenation procedures will afford the 2',3'-dideoxy-3'-hydroxymethyl-ribonucleosides. Nucleosides of this type can be selectively protected and the 3'-hydroxymethyl moiety functionalized to a variety of suitable electrophilic moieties. In accordance with preferred embodiments of this invention, such electrophilic moieties include halomethyl, trifluoromethyl, sulfonylmethyl, p-methylbenzene sulfonylmethyl, hydrazinomethyl or 3'-C-formyl.


The "downstream" nucleoside is generally modified at the 5' sugar site and is referred to hereinafter as "synthon 2". Modification to produce ribo and 2'-

deoxyribonucleosides of adenine, guanine, cytosine, uracil, thymine and their analogs, with their 5'-hydroxymethylene group converted into various types of electrophilic centers can be accomplished through various procedures using commercially available nucleosides. For example, 5'-deoxy-5'-halo nucleoside, 5'-deoxy-5'-tosyl nucleosides, and 5'-aldehydic nucleosides have been prepared by Jones, G.H. and J.G. Moffatt in *Journal of the American Chemical Society* 90:5337-5338 (1968).

- 10 In general, synthon 1 can be represented as comprising the structure:



while synthon 2 generally comprises the structure:



- 15 wherein B_x is a variable base moiety; Q is O, CH_2 , CHF or CF_2 ; and E_1 and E_2 are the same or different and are electrophilic reactive groups.

- The two synthons are coupled via a linking group reactive with the electrophilic reactive groups or otherwise. Coupling between synthon 1 and synthon 2 can occur either stepwise or in a concerted manner and can result in dinucleosides linked through the modified linkage of the present invention or can result in a chain of nucleosides, each of which can be linked to the next through said modified linkage.

- 25 Coupling via a concerted action can occur between the electrophilic centers of synthon 1 and synthon 2 such as in the presence of ammonia or an ammonia derivative to produce a dinucleoside. A preferred embodiment of the

- 24 -

present invention is the coupling of known, bromomethyl type synthons by the addition of hydrazine to produce a preferred linkage having $-L_1-L_2-L_3-L_4-$ equal to $-\text{CH}_2\text{NHNHCH}_2-$.

Another preferred embodiment of the present invention is the coupling of bromomethyl type synthons by the addition of hydroxylamine to produce a linkage having $-L_1-L_2-L_3-L_4-$ equal to $-\text{CH}_2\text{NHOCH}_2-$ or $-\text{CH}_2\text{ONHCH}_2-$.

Another procedure whereby inter-sugar linkages can be modified to provide the dinucleoside structure described herein is via a Wittig reaction. Preferably, the starting material of such reaction is a 3'-keto nucleoside such as described by Townsend, et al. in *Tetrahedron Letters* 31:3101-3104 (1990); Samano, V. and M.J. Morris in *Journal of Organic Chemistry* 55:5186-5188 (1990); and Bergstrom, D.E., et al. in *Nucleosides and Nucleotides* 8(8):1529-1535 (1989); or a 5'-aldehydic nucleoside as described by Jones, G.H. and J.G. Moffatt in *Journal of the American Chemical Society* 90:5337-5338 (1968). The starting material is preferably reacted with a phosphorus ylide having a benzyl or other protecting group. One preferred ylide useful for this invention is triphenylphosphorane-benzyloxymethylidene. Another useful ylide preferably used for this invention is triphenylphosphorane-benzyloxyethylidene. Reduction of the vinyl group and hydrogenolysis of the benzyl protecting group provides hydroxymethyl and hydroxyethyl moieties respectively, in the 5' or 3' positions of the desired nucleoside of guanine, adenine, cytosine, thymine, uracil or the analogs of these nucleosides. In addition, the Wittig reaction can be used to provide the 5' and 3' hydroxy alkyl moieties of carbocyclic nucleosides.

Conversion of the hydroxyl groups to provide electrophilic centers and subsequent coupling of a 3' electrophilic center with a 5' nucleophilic center will afford dinucleosides of the present invention. In one embodiment of the invention, the hydroxyl groups are converted to provide electrophilic centers such as

- 25 -

bromides, triflates, and tosylates. Coupling affords dinucleosides connected by a carbon chain with one or two heteroatoms. Preferably such heteroatoms are O, NH, NR_3 , S, SO, SO_2 , $\text{P}(\text{O})\text{R}_4$, $\text{P}(\text{S})\text{R}_4$ or SiR_5R_6 as depicted in the generic formula provided previously.

Other useful dinucleosides which likely can be derived from a Wittig reaction involving 3' or 5' carbonyl nucleosides and triphenylphosphorine methylidene diphenylphosphonate are phosphonate dinucleosides. This reaction provides a methyl or ethyl phosphonate which can be condensed with the corresponding 5'- or 3'-hydroxy group to provide 3'- or 5'-phosphonate linked oligonucleosides. Chemistry of this type has been described in the preparation of phosphonates of dinucleosides for the study of biochemical processes, Moffatt, J.G., et al., *Journal of American Chemical Society* 92:5510-5513 (1970) and Mazur, A., B.E. Tropp, and R. Engel, *Tetrahedron* 40:3949-3956 (1984). Utilizing this type of coupling, a preferred embodiment is prepared by the coupling a 3'-keto nucleoside to a 5'-nucleoside with a symmetrical bis(methyltriphenylphosphane)phenylphosphate to provide 3',5'-dimethylphosphonate linked oligonucleotides.

In addition to the Wittig reaction, 3'-hydroxymethyl nucleosides can also be prepared by inversion of alpha carbocyclic nucleosides. This will provide the desired 3' hydroxymethyl group on the "down" or alpha face. This group can be protected and the 3''-hydroxyl group (identifying the exo-cyclic methyl linked to the sugar 3' position as 3'' methyl) can be converted to a hydroxymethyl group or to a longer alkyl group. One method of converting the 3'' group involves oxidation to a keto group, followed by a Wittig reaction with triphenylphosphorine methylidene diphenylphosphonate and reduction. Longer hydroxyalkyl groups can be placed in the 3''-position in this manner. This embodiment also provides a 4'-desmethyl-3'-hydroxymethyl nucleoside synthon. Coupling this 4'-desmethyl nucleoside and a normal 3'-hydroxy- nucleoside

- 26 -

using a two atom coupler will provide dinucleoside synthons as described in prior pending application Serial No. 566,836 filed August 13, 1990, which application is assigned to the assignee of this application. Coupling of
5 the 4'-desmethyl hydroxyl group with appropriate 3'-synthons as described above will provide a number of other types of novel dinucleoside synthons.

Yet another approach to functionalize the methyl group of 3'-deoxy-3'-methyl nucleosides can be elaborated
10 from 3'-deoxy-3'-cyanonucleosides. Parkes, K.E.B., and K. Taylor, *Tetrahedron Letters* 29:2995-2996 (1988) described a general method of synthesis of 3'-cyano nucleosides. In this method, 5'-trityl protected 2'-deoxynucleosides are 3'-iodinated with methyltriphenylphosphonium iodide. These
15 materials are then treated with hexamethylditin, t-butylisonitrile, and 2,2'-azo-bisisobutyronitrile (AIBN) to provide the radical addition of a cyano group to the 3'-position. Conversion of the cyano group to an aldehyde was accomplished in high yield. Subsequently, the intermediate
20 was converted to hydroxymethyl functions, which are valuable precursors to the electrophilic synthon 1.

An additional procedure whereby inter-sugar linkages can be modified to provide dinucleosides utilizes 3'-C-formyl derivatized nucleosides as synthon 1 and 5'-
25 aminohydroxy derivatized nucleosides as synthon 2. Direct coupling of synthons 1 and 2 gave a dinucleoside coupled via an oxime linkage. In this instance, the oxime is present as E/Z isomers. The isomeric compounds are separated utilizing HPLC. Further in this instance, the
30 oxime nitrogen atom is adjacent to a carbon atom on the 3'-end of the upstream nucleoside. Dinucleosides having the oxime nitrogen adjacent to a carbon atom on the 5' or downstream nucleoside are synthesized utilizing a 5'-C-formyl derivatized nucleoside as synthon 2 and a 3'-deoxy-
35 3'-aminohydroxymethyl derivatized nucleoside as synthon 1. In this instance, oxime E/Z isomers are also obtained. In both instances the oxime linked dimers are useful for

- 27 -

direct incorporation into an oligomer or can be reduced to the corresponding hydroxyamino linked dinucleoside.

Reduction of oxime linked dinucleosides either as the dinucleoside or as a dinucleoside moiety in an oligomer

5 with sodium cyanoborohydride yields the corresponding aminohydroxyl linked compounds. The hydroxyamino linked dinucleoside or a large oligomer could be alkylated at the amino moiety of the aminohydroxyl linkage to yield a corresponding N-alkylamino linkage.

10 The 3'-C-formyl derivatized synthon 1 can be formed via several synthetic pathways. The presently preferred method utilizes a radical carbonylation of the corresponding 3'-deoxy-3'-iodo nucleoside. The iodo compound is treated with CO, AIBN, i.e., 2,2'-
15 azobisisobutyronitrile, and TTMS, i.e. tris(trimethylsilyl)silane. Alternately, it can be synthesized from either a 3'-deoxy-3'-cyano sugar or nucleoside. Both 5'-C-formyl (also identified as 5'-aldehydo) and 3'-C-formyl group can be blocked in a facile
20 manner utilizing o-methylaminobenzenthion as a blocking group. Both of the 5' and the 3' -C-formyl groups can be deblocked with silver nitrate oxidation.

In an alternate method of 3'-C-formyl nucleoside synthesis, 1-O-methyl-3'-deoxy-3'-O-methylaminobenzene
25 thiol-5'-O-trityl-β-D-erythro-pento furanoside can be used for its preparation. This compound then serves as a precursor for any 3'-deoxy-3'-C-formyl nucleoside. The 1-O-methyl-3'-deoxy-3'-O-methyl amino benzenethiol-5'-O-trityl-β-D-erythro-pentofuranoside is reacted with an
30 appropriate base utilizing standard glycosylation conditions followed by deblocking to yield the nucleoside. In even a further alternate method, a 3'-deoxy-3'-cyano nucleoside is prepared from either the corresponding 3'-deoxy-3'-iodo nucleoside or via a glycosylation reaction
35 with 1-O-methyl-3'-deoxy-3'-O-cyano-5'-O-trityl-β-D-erythro-pentofuranoside.

- 28 -

The 3''-O-amino-3''-hydroxymethyl nucleoside and the corresponding 5'-O-amino nucleoside can be conveniently prepared via a protected phthalimido intermediate via Mitsunobu conditions using N-hydroxyphthalimide, triphenylphosphine and diisopropylazodicarboxylate. This in turn is prepared by a Mitsunobu reaction on the unprotected hydroxyl group of the nucleoside. In forming the 3''-O-amino-3''-hydroxymethyl nucleoside, trityl serves as a blocking group for the 5'-hydroxyl group of the nucleoside. For both purine and pyrimidine nucleosides, prior to reacting with N-hydroxyphthalimide the 3'-hydroxy group is protected with TBDPS. With pyrimidine bases, in forming the 5'-O-amino nucleoside the 3'-hydroxyl can be protected with TBDPS blocking groups after introduction of the phthalimido on the 5' position.

A further procedure whereby inter-sugar linkages can be modified to provide phosphonate linked dinucleotides utilizes the Michaelis-Arbuzov procedure of Mazur et al., *Tetrahedron*, 20:3949 (1984) for formation of 3'-C-phosphonate dimers. This procedure would utilize a 3'-hydroxymethyl nucleosides as synthon 1. This is treated with N-bromosuccinimide to yield the corresponding 3''-bromomethyl derivative. Synthon 2 is selected as a 5'-phosphite. Coupling of synthons 1 and 2 gives a dinucleoside coupled via a 3'-C-phosphonate linkage. The corresponding 5'-C-phosphonate dimers could be obtained by first reacting a suitable blocked phosphite with synthon 1 followed by deblocking to yield the 3'-CH₂-phosphite intermediate. Synthon 2 is selected as a 5'-bromonucleoside. The 3'-CH₂-phosphite intermediate is then reacted with synthon 2 to give the 5'-C-phosphate dimer. By selecting tribenzylphosphite as the blocked phosphite after coupling to synthon 1 the benzyl groups can be removed by hydrogenolysis. Alternately a 5'-deoxy-5'-bromonucleoside is reacted with a phosphite ester resulting in a 5'-phosphonate. This, in turn, is reacted with 3'-

- 29 -

hydroxymethyl nucleoside to yield the 5'-C-phosphonate linked dimer.

Resulting dinucleosides from any of the above described methods, linked by hydrazines, hydroxyl amines and other linking groups of the inventions, can be protected by a dimethoxytrityl group at the 5'-hydroxyl and activated for coupling at the 3'-hydroxyl with cyanoethyldiisopropylphosphite moieties. These dimers can be inserted into any desired sequence by standard, solid phase, automated DNA synthesis utilizing phosphoramidite coupling chemistries. Therefore, the protected dinucleosides are linked with the units of a specified DNA sequence utilizing normal phosphodiester bonds. The resulting oligonucleotide analog or oligomer has a mixed backbone -- part normal phosphodiester links and part novel four atoms links of the inventions. In this manner, a 15-mer, sequence-specific oligonucleotide can easily be synthesized to have seven hydroxylamine, hydrazine or other type linked dinucleosides. Such a structure will provide increased solubility in water compared to native phosphodiester linked oligonucleotides.

Oligonucleosides containing an uniform backbone linkage can be synthesized by use of CPG-solid support and standard nucleic acid synthesizing machines, i.e., Biosystems Inc. 380B and 394 and Milligen/Biosearch 7500 and 8800s. The initial nucleoside (number 1 at the 3'-terminus) is attached to a solid support such as controlled pore glass. Each new nucleoside is attached in sequence specific order either by manual manipulation or by the automated synthesizer system. In the case of a methylenehydrazine linkage, the repeating nucleoside unit can be of two general types, e.g., a nucleoside with a 5'-protected aldehydic function and a 3'-deoxy-3'-C-hydrazinomethyl group, or a nucleoside bearing a 5'-deoxy-5'-hydrazino group protected by an acid labile group and a 3'-deoxy-3'-C-formyl group. In each case, the conditions which are repeated for each cycle to add the subsequent

- 30 -

sequence required base include: acid washing to remove the 5'-aldehyde protecting group; addition of the next nucleoside with a 3'-methylenehydrazino group to form the respective hydrazone connection; and reduction with any of a variety of agents to afford the desired methylene-hydrazine linked CPG-bound oligonucleosides. One such useful reducing agent is sodium cyanoborohydride.

A preferred method is depicted in Figure 1. This method employs a solid support on which a synthon 2 with a protected 5' site is bound. Preferably, the 5' site of said synthon can be protected with DMT. Thereafter, the 5' site of the synthon 2 is liberated with mild acid, washed, and oxidized to produce an intermediate product. In one preferred method, the aldehyde derivative reacts with N,N-diphenylethylene diamine to produce an intermediary product, 5'-diphenylimidazolidino protected synthon 2. In a more preferred method, the 5'-diphenylimidazolidino protected synthon 2 is directly loaded on the support. With either method, the intermediary product can be subsequently deblocked to provide a synthon 2 with a nucleophilic 5' position. Addition of a synthon 1 with a protected 5'-aldehyde group, such as a 5'-diphenylimidazolidino protected 3'-deoxy-3'-C-hydrazine base, can then react, such as by the addition of sodium cyanoborohydride, with the attached synthon 2. Following a wash, a dinucleoside linked through a hydrazino moiety is formed. Thereafter, the cycle can be repeated as desired by the addition of a synthon 1 species followed by acid/base deprotection to create a polysynthon -- a resulting oligomer of a desired sequence -- linked together through modified inter-sugar linkages. In some preferred embodiments of this invention, the synthon 1 species can be a 5'-DMT protected 3'-C-hydrazine base.

One preferred embodiment of this stepwise process utilizes a diphenylethyldiamine adduct (1,3-disubstituted imidazolidino) to protect the electrophilic center of synthon 2 during attachment to the solid support. Moffatt,

- 31 -


J.G., et al., *Journal of American Chemical Society* 90:5337-5338 (1968). Synthon 2 preferably can be attached to a solid support such as a controlled pore glass support or other suitable supports known to those skilled in the art.

5 Attachment can take place via a standard procedure. Gait, M.J., ed., *Oligonucleotide Synthesis, A Practical Approach* (IRL Press 1984). Alternatively, preparation can occur by directly oxidizing the protected bound nucleoside with various standard oxidizing procedures. Bound synthon 2 is
10 preferably reacted with hydrazine to produce a Schiff's base which can be subsequently reduced. Hydroxylamine is also a preferred reactant useful in this method.

A further method of synthesizing uniform backbone linked oligonucleosides is depicted in Figure 2. This
15 method also employs a solid support on which a synthon 2, with a protected 5' site is bound. In this instance, the 5' site of the synthon is protected with a phthalimido group. Thereafter, the 5' site of the synthon 2 is liberated with methylhydrazine in DCM and washed with
20 DCM:methanol. The aminohydroxyl group at the 5' position of synthon 1 is also protected with a phthalimido group. Such synthon 1 is a 5'-phthalimido protected 3'-deoxy-3'-C-formyl nucleoside. Synthon 1 is reacted with synthon 2 followed by deprotection at the 5' position and washing to
25 liberate the next 5'-aminohydroxy reaction site. The cycle is repeated with the further addition of synthon 1 sufficient times until the desired sequence is constructed. Each nucleoside of this sequence is linked together with an oxime linkage. The terminal nucleoside of the desired
30 oligonucleoside is added to the sequence as a 5'-DMT blocked 3'-deoxy-3'-C-formyl nucleoside. The oxime linked oligonucleoside can be removed from the support. If a aminohydroxyl linked oligonucleoside is desired the oxime linkages are reduced with sodium cyanoborohydride.
35 Alternately, reduction can be accomplished while the oxime linked oligonucleoside is still connected to the support.

- 32 -

Also in accordance with this invention, nucleosides are provided having the structure:



wherein B_x is a variable base moiety; Q is O, CH_2 , CHF or CF_2 ; X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide.

In such species, Y is hydroxyl, aminomethyl, hydrazinomethyl, hydroxymethyl, C-formyl, phthalimidohydroxymethyl, aryl-substituted imidazolidino, aminohydroxylmethyl, methylaminobenzenethio, methylphosphonate and methyl-alkyl phosphonate; and Z is H, hydroxyl, aminomethyl, hydrazinomethyl, hydroxymethyl, C-formyl, phthalimidohydroxymethyl, aryl substituted imidazolidino, aminohydroxylmethyl, ortho-methylaminobenzenethio, methylphosphonate or methyl alkylphosphonate.

All of the foregoing is with the proviso that when Q is O and Y is hydroxymethyl and X is H or OH then Z is not C-formyl; and when Q is O and X is H or OH and Z is hydroxyl then Y is not aminohydroxylmethyl, hydrazinomethyl or aryl-substituted imidazolidino.

The oligonucleotide analogs of this invention can be used in diagnostics, therapeutics, and as research reagents and kits. For therapeutic use the oligonucleotide analog is administered to an animal suffering from a disease modulated by some protein. It is preferred to

- 33 -

administer to patients suspected of suffering from such a disease an amount of oligonucleotide analog that is effective to reduce the symptomology of that disease. One skilled in the art can determine optimum dosages and treatment schedules for such treatment regimens.

It is generally preferred to administer the therapeutic agents in accordance with this invention internally, such as orally, intravenously, or intramuscularly. Other forms of administration, such as transdermally, topically, or intra-lesionally can also be useful. Inclusion in suppositories can also be useful. Use of pharmacologically acceptable carriers is also preferred for some embodiments.

- 34 -

EXAMPLES

The following examples are illustrative, but not limiting, of the invention.

SYNTHESIS OF UNIFORM METHYLENEHYDRAZINE**5 (3'-CH₂-NH-NH-CH₂-5') LINKED OLIGONUCLEOSIDES****EXAMPLE 1**

Synthesis of CPG-bound nucleosides; diphenylimidazolidino protected 5'-aldehydic thymidine and 5'-deoxy-5'-hydrazino-thymidine.

- 10 CPG-bound thymidine (30 micromoles of thymidine on one gram of CPG support, ABI, Foster City, Ca) is treated at ambient temperature with a mixture of DMSO, benzene, DCC, pyridine, and trifluoroacetic acid (15 ml/15 ml/ 2.48 g/ 0.4 ml/ 0.2 ml, similar to the oxidation
15 procedure of Pfitzer, K.E. and J.G. Moffatt, *Journal of American Chemical Society* 85:3027 (1963), to provide 5'-aldehydic nucleosides. The mixture is filtered after storing overnight. The support is washed with oxalic acid (1.3 g in 5 ml benzene/DMSO, 1 to 1) and treated with
20 1,2-dianilinoethylene (3.0 g) for one hour, filtered, and washed with acetonitrile to afford the 5'-diphenylimidazolidino protected 5'-aldehydic thymidine. Treatment of the support-bound 5'-aldehydo thymidine with a solution of hydrazine hydrate/sodium cyanoborohydrate in
25 acetonitrile provides CPG-3'-bound 5'-deoxy-5'-hydrazino thymidine, which is stored as its hydrochloride salt.

EXAMPLE 2

Synthesis of 5'-diphenylimidazolidino protected-3'-deoxy-3'-C-hydrazinomethyl thymidine.

- 30 Commercially available 3'-O-acetylthymidine was oxidized and subsequently protected as its N,N-diphenylethylenediamine derivative (1,3-diphenylimidazolidino). This provides the known 5'-deoxy-5'-diphenylimidazolidino-3'-acetylthymidine.

- 35 -

Pfitzer, K.E. and J. G. Moffatt, *Journal of American Chemical Society* 85:3027 (1963). Hydrolysis of this material was achieved by methanolic ammonia treatment at ambient temperature for 15 hours. 5'-Deoxy-5'-

- 5 diphenylimidazolidinethymidine (4.5 g) was dissolved in DMF (100 ml) and treated with triphenylmethyl phosphonium iodide at room temperature for 15 hours. The solvent was removed under reduced pressure and the resulting residue recrystallized from methanol to provide the
- 10 3'-deoxy-3'-iodo derivative.

- The 3'-deoxy-3'-iodo-5'-diphenylimidazolino thymidine was dissolved in toluene and treated with hexamethylditin, t-butylisonitrile, and AIBN. This radical reaction provides the 3'-deoxy-3'-cyano derivative which
- 15 was subsequently reduced with diisobutylaluminum hydride (DIBAL-H) in toluene/THF at 0°C, to afford 3'-deoxy-3'-C-formyl-5'-diphenylimidazolidino thymidine. This material was treated with hydrazine hydrate and sodium borohydride in acetonitrile to afford 5'-diphenylimid-
- 20 azolidino protected-3'-deoxy-3'-C-hydrazinomethyl thymidine. The material is conveniently stored as the acetate salt.

EXAMPLE 3

- Synthesis of uniform methylenehydrazine linked
- 25 oligonucleosides via an Applied Biosystems Inc 380B DNA Synthesizer.

- CPG-bound thymidine with a diphenylimidazolidino protected 5'-aldehyde that will become the 3'-terminal nucleoside is placed in an Applied Biosystems, Inc. (ABI)
- 30 column (250 mg, 10 micromoles of bound nucleoside) and attached to an ABI 380B automated DNA Synthesizer. The automated (computer controlled) steps of a cycle that are

- 36 -

required to couple a desmethyl nucleoside unit to the growing chain are as follows.

| STEP | REAGENT OR SOLVENT MIXTURE | TIME (min:sec) |
|------|---|----------------|
| 1 | 3% DCA in dichloroethane | 3:00 |
| 5 2 | Dichloroethane wash | 1:30 |
| 3 | 5'-Deoxy-5'-(1,3-diphenylimid-azolidino)-3'-deoxy-3'-C-methylene hydrazine nucleoside (the second nucleoside); 20 micromoles in 30 ml of acetonitrile | 2:50 |
| 10 4 | Sodium borohydride (50 micromole in 1:1 THF/EtOH, 50 ml) | 3:00 |
| 5 | Dichloroethane wash | 2:00 |
| 6 | Recycle starting at step 1 (acid wash) | 3:00 |

15 This procedure yields as its product nucleoside the 5'-dimethoxy trityl substituted nucleoside unit.

At the completion of the synthesis, base deprotection and oligomer removal from the support is accomplished by standard procedures. Trityl-on HPLC purification followed by acetic acid deprotection and precipitation provides the oligonucleosides as the acetate salts.

SYNTHESIS OF INTERMITTENT METHYLENEHYDRAZINE (3'-CH₂-NH-NH-CH₂-5') LINKED OLIGONUCLEOSIDES

25 EXAMPLE 4

Synthesis of 5'-Deoxy-5'-hydrazinothymidine Hydrochloride

To provide 5'-Benzylcarbazy-5'-deoxythymidine, 5'-O-tosylthymidine, *Nucleosides & Nucleotides* 9:89 (1990) (1.98g, 5 mmol), benzylcarbazine (4.15 g, 25 mmol), activated molecular sieves (3A, 2 g), and anhydrous dimethyl- acetamide (100 ml) were stirred together with exclusion of moisture at 110°C (bath temperature) for 16 hours. The products were cooled and concentrated under

- 37 -

reduced pressure (bath temperature $<50^{\circ}\text{C}$). The residue was purified on a silica gel column (5 X 45 cm) with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (9:1, vol/vol) as the solvent. The homogeneous fractions were pooled, evaporated to dryness and the foam

5 recrystallized from EtOH to yield 0.7 g (36 %) of 5'-benzylcarbazyl-5'-deoxythymidine; mp 201°C ; ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.79 (s, 3, CH_3), 2.00-2.18 (m, 2, C_2, CH_2), 2.95 (t, 2, C_5, CH_2), 3.75 (m, 1, C_4, H), 4.18 (m, 1, C_3, H), 4.7 (brs, 1, O_2NH), 5.03 (s, 2, PhCH_2), 5.2 (d, 1, C_3, H),
10 6.16 (t, 1, C_1, H), 7.2-7.4 (m, 5, C_6H_5), 7.6 (s, 1, C_6H), 8.7 (brs, 1, CH_2NH), 11.2 (brs, 1, C_3NH).

To provide the hydrochloride salt of 5'-deoxy-5'-hydrazinothymidine as a hygroscopic powder, a mixture of the above carbazate (0.78 g, 2 mmol) and palladium on
15 charcoal (10%, 150 mg) in anhydrous MeOH/HCl (30 ml, 2%, HCl by weight) was stirred under an atmosphere of hydrogen at room temperature for 1.5 hours. The methanolic solution was filtered through Celite to remove the catalyst. The filter cake was washed with EtOH (2 X 25 ml). The filtrate
20 was concentrated under vacuum and the residue was dried overnight to remove traces of HCl. The yellow residue was dissolved in methanol (3 ml) and added dropwise to a rapidly stirred solution of ethyl acetate (150 ml). The filtered precipitate was washed with ethyl acetate (3 X 100
25 ml) and the pale yellow solid was dried under vacuum to yield 0.51 g (88%) of 5'-deoxy-5'-hydrazinothymidine hydrochloride (hygroscopic powder); ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.81 (s, 3, CH_3), 2.02- 2.22 (m, 2, C_2, CH_2), 3.2 (m, 2, C_5, CH_2), 3.8 (m, 1, C_4, H), 4.2 (m, 1, C_3, H), 6.17 (t, 1, C_1, H),
30 7.54 (s, 1, C_6H), 11.18 (brs, 1, C_3NH), the hydrazino and 3'-OH were not seen because the sample was wet.

- 38 -

EXAMPLE 5

Synthesis of 5'-Trityl-1-[2,3-dideoxy-3-C-(formyl)- β -D-erythro-pentofuranosyl] uracil and thymine

To a stirred solution of 3'-cyano-2',3'-dideoxy-5'-O-trityl uridine (0.96 g, 2 mmol), (see Tetrahedron Letters 29:2995 (1988) for synthesis of the thymidine analog) in dry THF (20 ml) under argon was added a solution of DIBAL-H in toluene (Aldrich) (1M, 4 ml) at -10°C over a period of 10 min. After 30 mins the reaction was quenched with MeOH (5 ml) at -10°C. The mixture was further stirred at ambient temperature for 30 mins and diluted with CH₂Cl₂ (25 ml) before concentrating under vacuum. This process was repeated with CH₂Cl₂ (3 X 25 ml) in order to remove the residual THF. The residue was purified by flash chromatography on silica gel (25 g). Elution with CH₂Cl₂ (9:1, v/v) and crystallization from CH₂Cl₂/MeOH gave 5'-O-trityl-3'-C-formyl-2',3'-dideoxyuridine (0.53 g, 53%); mp 100°C; ¹H NMR (CDCl₃) δ 2.25 - 2.8 (m, 2, CH₂), 3.4 (m, 1, C₃H), 3.45 - 3.6 (m, 2, C₅CH₂), 4.37 (m, 1, C₄H), 5.4 (d, 1, C₅H), 6.1 (m, 1, C₁H), 7.2 - 7.4 (m, 15, C₆H₅), 7.81 (d, 1, C₆H), 7.95 (brs, 1, NH), 9.61 (s, 1, HC=O).

EXAMPLE 6

Synthesis of 1-Methyl-5-(t-butyldiphenylsilyl)-2,3-dideoxy-3-C-(formyl)-D-erythropentofuranose

The 3'-C-formyl sugar precursor was obtained as an oil in 90% yield using the DIBAL-H reduction for the 3'-C-cyanosugar, Tetrahedron Letters 44:625 (1988), described above.

EXAMPLE 7

Synthesis of Methylenehydrazine Linked (3'-CH₂-NH-NH-CH₂-5') 5'-Dimethoxytrityl-3'- β -cyanoethoxydiisopropylphosphoramidite Dinucleosides

To a stirred solution of 5'-O-trityl-1-[2,3-dideoxy-3-C-(formyl)- β -D-erythro-pentofuranosyl] thymine (1 mmol), 5'-deoxy-5'-hydrazinothymidine hydrochloride (1, mmol), and

- 39 -

dry THF (25 ml) under argon was added dried molecular sieves (1 g). The reaction was allowed to proceed overnight and then was treated with bromocresol green (5 mg). Sodium cyanoborohydride (4 mmol) was then added, followed by dropwise addition via syringe of *p*-toluenesulfonic acid in THF (4 mmol in 4 ml) in such a way that the tan color of the reaction mixture was maintained. Stirring was continued for two hours after the addition. The mixture was filtered and the solids were washed with dry MeOH (3 X 10 ml). The combined filtrates were pooled and concentrated. The residue was purified by column chromatography to afford methylenehydrazine linked (3'-CH₂-NH-NH-CH₂-5') thymidine dimers. The hydrazino linkage of this material was monobenzoylated via the transient method described in Gait, M.J., ed., *Oligonucleotide Synthesis, A Practical Approach* (IRL Press 1984). The 5'-hydroxyl and 3'-hydroxyl are converted to the 5'-O-dimethoxytrityl-3'-β-cyanoethoxydiisopropylphosphoramidite according to standard procedures.

20. EXAMPLE 8

Synthesis of Intermittent Methylenehydrazine (3'-CH₂-NH-NH-CH₂-5') Linked Oligonucleosides

CPG-bound thymidine (or any other nucleoside that is to become the 3'-terminal base) is placed in an Applied Biosystems, Inc. (ABI) column (250 mg, 10 micromoles of bound nucleoside) and attached to an ABI 380B automated DNA Synthesizer. The standard, automated (computer controlled) steps utilizing phosphoramidite chemistries are employed to place the methylenehydrazine thymidine dimer into the sequence at any desired location.

EXAMPLE 9

Alternate synthesis of 5'-O-trityl-1-[2,3-dideoxy-3-C(formyl)-β-D-erythro-pentofuranosyl]-uracil and -thymine

A mixture of 3'-deoxy-3'-iodo-5'-O-tritylthymidine (0.59 g, 4 mmol); *Tet. Letters*, 29:2995 (1988),

- 40 -

tris(trimethylsilyl) silane (2.87 g, 1.2 mmol), AIBN (12 mg, 0.072 mmol), and toluene (20 ml) were mixed in a glass container and saturated with argon (bubbling at room temperature). The glass vessel was inserted into a stainless steel pressure reactor, pressurized with carbon monoxide (80 psi), closed, and heated (90°C, bath) for 26 hrs. The reaction mixture was cooled (0°C) and CO was allowed to escape carefully (under the fume hood). The product was purified by flash column chromatography on silica gel (20 g). Elution with EtOAc:Hexanes (2:1, v/v) and pooling the appropriate fractions furnished 0.30 g (61%) of the title compound as a foam.

A radical carbonylation of 2',3'-dideoxy-3'-iodo-5'-O-trityluridine in a similar manner gives the 3'-C-formyl uridine derivative.

EXAMPLE 10

Synthesis of 5'-O-phthalimidothymidine and 2'-deoxy-5'-O-phthalimidouridine

To a stirred mixture of thymidine (1.21 g, 5 mmol), N-hydroxyphthalimide (1.09 g, 6.6 mmol), triphenylphosphine (1.75 g, 6.6 mmol), in dry DMF (25 ml) was added diisopropylazodicarboxylate (1.5 ml, 7.5 mmol) over a period of 30 min at 0°C. The stirring was continued for 12 hrs at room temperature. The solvent was evaporated under vacuo and the residue washed with diethyl ether (2x50 ml). The residue was suspended in hot EtOH (50 ml), cooled and filtered to furnish 1.54 g (80%) of the title compound as a white powder.

An analogous reaction on 2'-deoxyuridine gave the corresponding 2'-deoxy-5'-phthalimidouridine; mp 241-242°C.

EXAMPLE 11

Synthesis of 5'-O-phthalimido-3'-O-tert-butyl(diphenyl)-silylthymidine and 2'-deoxy-5'-O-phthalimido-3'-O-tert-butyl(diphenyl)silyluridine

- 5 Treatment of 5'-O-phthalimidothymidine or 2'-deoxy-5'-O-phthalimidouridine with tert-butyl(diphenyl)-chlorosilane in pyridine and imidazole in a standard manner afforded 5'-O-phthalimido-3'-O-tert-butyl(diphenyl)-silylthymidine and 2'-deoxy-5'-O-phthalimido-3'-O-tert-
- 10 butyl(diphenyl)silyluridine as crystalline products. ¹H NMR of the thymidine derivative in CDCl₃: δ 1.10 (s, 9, C(CH₃)₃), 1.95 (s, 3, CH₃), 2.2 (m, 2, C₂, CH₂), 3.63-4.15 (m, 3, C₃, H and C₅, CH₂), 4.80 (m, 1, C₄, H), 6.45 (t, 1, C₁, H), 7.4 (m, 15, ArH, C₆H), 8.2 (br s, 1, NH).

15 **EXAMPLE 12**

Synthesis of 5'-O-amino-3'-O-tert-butyl(diphenyl)silylthymidine

- To a stirred mixture of 5'-O-phthalimido-3'-O-tert-butyl(diphenyl)silylthymidine in dry CH₂Cl₂ (10 ml) was
- 20 added methylhydrazine (3 mmol) under anhydrous conditions at room temperature. The solution was stirred for 12 hrs, cooled (0°C) and filtered. The precipitate was washed with CH₂Cl₂ (2 x 10 ml) and combined filtrates were concentrated. The residue was purified by flash column chromatography
- 25 (silica gel, 20 g). Elution with CH₂Cl₂:MeOH (9:1, v/v) furnished the desired 5'-O-amino-3'-O-tert-butyl(diphenyl)silylthymidine as a crystalline product (65%): ¹H NMR (CDCl₃) δ 1.0 (s, 9, C(CH₃)₃), 1.80 (s, 3, CH₃), 1.81 and 2.24 (2 m, 2, C₂, CH₂), 3.25 and 3.60 (2 m,
- 30 2, C₅, CH₂), 4.0 (m, 1, C₃, H), 4.25 (m, 1, C₄, H), 5.4 (v br, s, NH₂), 6.25 (t, 1, C₁, H), 7.2 (s, 1, C₆H), 7.25-7.60 (m, 10, ArH), 8.4 (br s, 1, NH).

- 42 -

EXAMPLE 13**Synthesis of (3'-CH=N-O-CH₂-5') and (3'-CH₂-NH-O-CH₂-5') linked oligonucleosides**

A mixture of 3'-deoxy-3'-C-formyl-5'-O-tritylthymidine (0.99 g, 2 mmol), and 5'-O-amino-3'-O-tert-butyl(diphenyl)silylthymidine (0.99 g, 2 mmol) in dry CH₂Cl₂ (25 ml) was stirred for 1 hr at room temperature. The solvent was evaporated under vacuo and the residue dissolved in dry THF (20 ml). A THF solution of tetrabutylammonium fluoride (1 M, 5 ml) was added to the stirred reaction mixture. The stirring was continued for 1 hr at room temperature, and the solvent evaporated to furnish a gummy residue. The residue was purified by short silica gel (20 g) column chromatography, and on elution with CH₂Cl₂:MeOH (99:4, v/v) furnished the desired dimer as a foam. The product was dissolved in anhydrous MeOH (50 ml) and to this a saturated methanolic HCl solution (2.5 ml) was added. The reaction mixture was stirred at room temperature for 15 hrs. Anhydrous pyridine (10 ml) was added to the above solution and the solvents evaporated to furnish the crude oxime linked dinucleoside. The oxime was purified by silica gel (20 g) column chromatography. Elution with CH₂Cl₂:MeOH (92:8, v/v) furnished 0.69 g (70%) of the oxime linked dimer as a mixture of E/Z isomers. ¹H NMR (DMSO-d₆) δ 1.78 and 1.80 (2 s, 6H, 2 CH₃), 2.02-2.40 (m, 4, 2C₂, CH₂), 3.15 (m, 1, C₃, H), 3.45 and 3.65 (2 m, 2, C₅, CH₂), 3.95 (m, 2, 2 C₄, H), 4.15-4.25 (m, 3, C₃, H, and C₅, CH₂), 5.20 (t, 1, ₅OH), 5.40 (d, 1, ₃OH) 6.05 (t, 1, C₁, H), 6.18 (t, 1, C₁, H), 6.85 (d, 1, C₃, H), 7.4 and 7.44 (2 s, 1, C₆H), 7.46 (d, 1, C₃, H), 7.78 and 7.80 (2 s, 1, C₆H) and 11.25 (2 br s, 2, NH).

The two geometrical isomers (E/Z) were separated by reverse phase HPLC and fully characterized by various analytical techniques. The isomeric dimer was further converted to its 5'-O-dimethoxytrityl derivative at the 5'-hydroxyl group of the dimer and its 3'-O-B-cyanoethoxydiisopropylphosphoramidite derivative at the 3'-

hy
31
15
cc
5 au
fc
va
li
cc
10 EX
Sy
O-
th
15 tc
sy
st
CH
de
20 se
EX
Sy
5'
sy
25
wa
Re
fc
30 ph
g-
(l
a)
pi

hydroxyl group of the dimer, utilizing standard chemistry. ³¹P NMR of this derivatized dimer in DMSO-d₆ resonated at δ 150.4, 150.7 and 150.8 ppm. The protected dimer can be conveniently stored and used for coupling utilizing an automated DNA synthesizer (ABI 380B) as and when required for specific incorporation into oligomers of therapeutic value. As is shown below, an oligomer bearing an oxime linked nucleoside dimer is reduced to an oligomer bearing a corresponding hydroxylamine linked nucleoside dimer.

10 **EXAMPLE 14**

Synthesis of Intermittent (3'-CH=N-O-CH₂-5') or (3'-CH₂-NH-O-CH₂-5') linked Oligonucleosides

An appropriate 2'-deoxynucleoside that will become the 3'-terminal nucleoside of an oligonucleoside is bound to a CPG column for use on an ABI 380B automated DNA synthesizer. Standard phosphoramidite chemistry program steps were employed to place the dimer bearing the (3'-CH=N-O-CH₂-5') or (3'-CH₂-NH-O-CH₂-5') linkages into the desired position or positions of choice within the sequence.

EXAMPLE 15

Synthesis of uniform (3'-CH=N-O-CH₂-5') or (3'-CH₂-NH-O-CH₂-5') linked oligonucleosides via an ABI 380B DNA synthesizer, utilizing 3 nucleoside subunits.

25 Subunit 1: CPG-bound 5'-O-phthalimidothymidine was prepared according to the procedure of *Nucleic Acids Research*, 18:3813 (1990), and used as a 3'-terminal unit for oligonucleoside synthesis.

30 Subunit 2: A bifunctional (3'-C-formyl and 5'-O-phthalimido deoxyribonucleoside) is derived by standard glycosylation of methyl 2,3-dideoxy-3-cyano-5-O-(phthalimido)-β-D-erythro-pentofuranoside with an appropriate base and DIBAL-H reduction of the nucleoside product.

- 44 -

Subunit 3: A 5'-O-DMT-3'-C-formyl thymidine is employed for the incorporation of the last (the 5'-end of the oligonucleoside) nucleoside.

The automated steps of a cycle that is required to synthesize a uniform linkage (on a 10 μ M scale : loading of unit 1 on CPG) are as follows:

| STEP | REAGENT/SOLVENT | Time/min |
|------|--|----------|
| 1 | 5% Methylhydrazine in DCM | 10 |
| 2 | DCM:MeOH (9:1, v/v) | 5 |
| 10 3 | DCM wash | 2 |
| 4 | 3'-C-formyl-5'-O-phthalimido-deoxyribo nucleoside (Unit 2, 20 μ M in 20 ml of DCM) | 3 |
| 5 | DCM:Acetone (9:1, v/v): Capping | 2 |
| 15 6 | DCM wash | 3 |

Foregoing steps 1 through 6 are repeated for each addition of a nucleoside unit depending on desired sequence and length. The final unit is then added:

| | | |
|---|--|---|
| 8 | Final nucleoside (20 μ M in 20 ml DCM) or Unit 3 | 5 |
|---|--|---|

NaCNBH₃ REDUCTION STEP FOR CONVERSION OF (3'-CH=N-O-CH₂-5') LINKAGE TO (3'-CH₂-NH-O-CH₂-5') IN A DIMER LINKAGE OR LINKAGES OF AN OLIGONUCLEOSIDE

EXAMPLE 16

25 Reduction of a Dimer

To a solution of a dimer (0.49 g, 1 mmol) in glacial acetic acid (AcOH) (5 ml) was added sodium cyanoborohydride (0.19, 3 mmol) in AcOH (1 ml), under an argon atmosphere at room temperature. The suspension was stirred for 1 hr, and an additional amount of NaBH₃CN in AcOH (1 ml) was added and stirring continued for 1 hr. The excess of AcOH was removed under reduced pressure at room temperature. The residue was coevaporated with toluene (2 x 50 ml) and

- 45 -

purified by silica gel (25 g) column chromatography. Elution with $\text{CH}_2\text{Cl}_2:\text{MeOH}$ (9:1, v/v) and pooling of appropriate fractions, followed by evaporation furnished 0.36 g (75%) of crystalline dimer.

5 EXAMPLE 17**Reduction of an Oligonucleoside**

CPG-bound oligonucleoside ($1\ \mu\text{M}$), that contains one (or more) backbone modified linkages is taken off the DNA synthesizer after completion of its synthesis cycles. A
10 $1.0\ \text{M}\ \text{NaBH}_3\text{CN}$ solution in $\text{THF}:\text{AcOH}$ (10 ml, 1:1 v/v) is pumped through the CPG-bound material in a standard way utilizing a syringe technique for 30 min. The column is washed with THF (50 ml), and reduced oligonucleoside is generated from the support column in a standard way.

15 EXAMPLE 18**Alternative Reduction of an Oligonucleoside**

As an alternative to the above reduction, reduction can also be accomplished after removal from the CPG support. At the completion of synthesis the
20 oligonucleoside is removed from the CPG-support by standard procedures. The 5'-O-trityl-on oligonucleoside is purified by HPLC and then reduced by the $\text{NaBH}_3\text{CN}/\text{AcOH}/\text{THF}$ method as described above.

EXAMPLE 19**25 Synthesis of (3'- $\text{CH}_2\text{-O-N=CH-5'}$) and (3'- $\text{CH}_2\text{-O-NH-CH}_2\text{-5'}$)
Linked Oligonucleosides**

3'-C-formyl-5'-O-tritylthymidine was reduced with an excess of NaBH_4 to furnish 3'-hydroxymethylthymidine which on treatment with triphenylphosphine, N-hydroxyphthalimide
30 and diisopropylazodicarboxylate in THF furnished 3'-phthalimidomethyl analog which upon hydrazinolysis using methylhydrazine gave 3'-hydroxymethyl-(O-amino)-5'-O-tritylthymidine in an overall yield of 64%.

- 46 -

1-(4-C-formyl-3-O-tert-butyl(diphenyl)silyl-2-deoxy-
β-D-erythro-pentofuranosyl)thymidine was prepared as per
the procedure of *Nucleosides and Nucleotides*, 9:533 (1990).
The coupling of this nucleoside with 3'-hydroxymethyl-(O-
amino)-5'-O-tritylthymidine in DCM as described above gave
the oxime which on NaCNBH₃CN reduction gave the dimer. The
dimer is suitably protected and activated as the 5'-O-DMT
and 3'-O-phosphoramidate derivative for insertion into
desired locations of oligonucleosides by standard DNA
synthesizer chemistry.

EXAMPLE 20

Synthesis of (3'-CH₂-P(O)₂-O-CH₂-5') and (3'-CH₂-O-P(O)₂-CH₂-5') Linked Oligonucleosides

A. Synthesis of 3'-C-phosphonate dimer

3'-hydroxymethyl-5'-(O-tert-butyl(diphenyl)silyl)-
thymidine is converted into its bromide by treatment with
NBS. The bromide is subjected to an Arbuzov reaction to
furnish the phosphonate diester. Cleavage of the
phosphonate diester with trimethylbromosilane gives the
free acid which on treatment with 3'-(O-tert-
butyl(diphenyl)silyl)thymidine and DCC in pyridine yields
the dimer.

B. Synthesis of 3'-C-phosphonate linked Oligonucleosides

The above dimer can be incorporated into an
oligonucleoside by suitably protecting and activating the
dimer as the 5'-O-DMT and 3'-O-phosphoramidate derivative for
insertion into desired locations in oligonucleosides by
standard DNA synthesizer chemistry.


C. Synthesis of 5'-C-phosphonate linked Oligonucleosides

The corresponding 5'-C-phosphonate dimers could be
obtained by reacting a 5'-deoxy-5'-bromonucleoside with a
phosphite ester, resulting in a 5'-phosphonate. This in
turn is reacted with a 3'-hydroxymethyl nucleoside to yield
the 5'-C-phosphonate linked dimer.

- 47 -


EXAMPLE 21

Synthesis of Compound (13), Structure (III) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(2-cyanoethyl- N,N,N',N'-tetraisopropyl phosphordiamidyl), and R_{E3} is H.



(III)

A. Compound (2), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is O-(p-toluene thioformyl), and R_{E3} is H.



(IV)

Compound (1) [structure (IV) wherein R_{E1} = O-t-butyldiphenylsilyl, R_{E2} = O-(p-toluene thioformyl, R_{E3} = H; 11.45 g; 23.82×10^{-3} mole] is dissolved under argon in CH_2Cl_2 (100 ml). To this solution is added NEt_3 (2.41 g; $23.82 \cdot 10^{-3}$ mole), DMAP (4-N,N-dimethylamino pyridine; 2.911

- 48 -

g; 23.82×10^{-3} mole), and p-toluene thiochloroformate (4.446 gr.; 23.82×10^{-3} mole). After 20 hours of stirring at room temperature, the mixture is diluted with CH_2Cl_2 (50 ml), washed with aq. NaH_2PO_4 (2 x 50 ml) then with brine (2 x 50 ml), and dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel (Hexane:AcOEt, 4:1). Compound (2) is isolated as a pale yellow solid (13.074 g; 20.72×10^{-3} mole; 87%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.41 ($\text{H}_{2'}$, ddd, $^2\text{J} = 13.5$, $^3\text{J}_{2',3'} = 5.9$; $^3\text{J}_{2',1'} = 9.3$); 2.73 ($\text{H}_{2'}$, dd, $^3\text{J}_{2',1'} = 5.0$); 4.36 ($\text{H}_{4'}$, ddd, $^3\text{J}_{3',4'} = 0.9$); 5.94 ($\text{H}_{3'}$, dd); 6.51 ($\text{H}_{1'}$, dd); 7.58 (H_6 , q, $^4\text{J} = 1.0$). MS (FD: m/e): 631 (M^+).

B. Compound (3), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is allyl, and $\text{R}_{\text{E}3}$ is H.

Compound (2) (5.0 g; 7.926×10^{-3} mole) is dissolved under argon in degassed benzene (79 ml: 0.1 M; degassed with a stream of argon for 30 minutes). After addition of allyl tri-n-butyltin (13.12 g; 39.63×10^{-3} mole) and AIBN (azo-bis isobutyronitrile; 0.65 g; 3.963×10^{-3} mole), the mixture is heated under reflux. After 4 hours, AIBN (0.26 g; 1.58×10^{-3} mole) is added again. No starting material is detected after 20 hours by analytical thin-layer chromatography (silica gel; Hexane:AcOEt, 1:1). The solvent is evaporated under reduced pressure and the residue is chromatographed on silica gel (Hexane:AcOEt, gradient 6:1 \rightarrow 2:1). Compound (3) is isolated as a white solid (3.12 g; 6.18×10^{-3} mole; 78%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.15-2.19 ($2\text{H}_{2'}$, m); 2.46 ($\text{H}_{3'}$, m); 5.70 ($\text{CH}=\text{CH}_2$; m); 6.11 ($\text{H}_{1'}$, dd $^3\text{J}_{1',2'} = 5.1$ and 6.1); 7.51 (H_6 , q, $^4\text{J} = 1.1$). MS(FD; m/e): 505 (M^+).

C. Compound (4), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is $\text{CH}_2\text{C}(\text{O})\text{H}$, and $\text{R}_{\text{E}3}$ is H.

Olefinic derivative (3) (3.11 g; 6.162×10^{-3} mole) is dissolved in a mixture of 2:1 dioxane- H_2O (60 ml). OsO_4 (0.157 g; 0.616×10^{-3} mole) is added, followed by a solution of NaIO_4 (2.89 g; 13.55×10^{-3} mole) in H_2O (25 ml). The suspension is stirred at room temperature for 4 hours.

CH_2Cl_2 then is added (100 ml). The organic phase is washed with brine (2 x 50 ml) and dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica-gel (Hexane:AcOEt, 1:1). Compound (4) is

5 obtained as a pale yellow solid (1.561 g; 3.08×10^{-3} mole; 50%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.07 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.9$, $^3\text{J}_{2',1'} = 7.0$, $^3\text{J}_{2',3'} = 7.9$); 2.39 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2',1'} = 4.9$, $^3\text{J}_{2',3'} = 8.3$); 2.84 ($\text{H}_{3'}$, m); 3.72 ($\text{H}_{4'}$, ddd, $^3\text{J}_{3',4'} = 7.5$); 6.14 ($\text{H}_{1'}$, dd); 9.72 (CHO; dd).

10 D. Compound (5), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is $\text{CH}_2\text{C}(\text{O})\text{OCH}_3$, and $\text{R}_{\text{E}3}$ is H.

Aldehyde (4) (2.23 g; 4.401×10^{-3} mole) is dissolved in DMF (20 ml). MeOH (0.846 g; 26.40×10^{-3} mole) and PDC (pyridinium dichromate; 10.137 g; 26.40×10^{-3} mole) are
15 added. The resulting dark brown solution is stirred at room temperature for 20 hours, then diluted with CH_2Cl_2 (60 ml), and washed with NaH_2PO_4 (2 x 50 ml) and with brine (2 x 50 ml). After drying over Na_2SO_4 , the solvent is evaporated and the residue is chromatographed on silica gel

20 (Hexane:AcOEt, 2:1). Compound (5) (1.531 g; 2.869×10^{-3} mole; 65%) is isolated as a white solid. $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.17 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.3$, $^3\text{J}_{2',1'} = 7.0$, $^3\text{J}_{2',3'} = 7.2$); 2.33 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2',1'} = 5.0$, $^3\text{J}_{2',3'} = 8.3$); 2.82 ($\text{H}_{3'}$, m); 3.68 (COOMe, s); 6.15 ($\text{H}_{1'}$, dd).

25 E. Compound (6), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is $\text{CH}_2\text{C}(\text{O})\text{OH}$, and $\text{R}_{\text{E}3}$ is H.

Ester derivative (5) (7.197 g ; 13.4×10^{-3} mole) is dissolved in a 1:1 mixture of THF- H_2O (50 ml). A solution of NaOH 0.1 N (26.8 ml ; 26.81×10^{-3} mole) is added. After 18
30 hours of stirring at room temperature, an additional amount of 0.1 N NaOH (13.4 ml ; 13.4×10^{-3} mole) is introduced and the mixture is stirred for 2 hours, neutralized with HCl 1N, and extracted with CH_2Cl_2 (2 x 50 ml). The organic phase is washed with brine (2 x 50 ml) and dried over
35 Na_2SO_4 . After evaporation of the solvent, compound (6) is obtained as a white solid (6.38 g ; 16.03×10^{-3} mole; 91%).

$^1\text{H-NMR}$ (CDCl_3 , 250 MHz, δ (ppm)): 6.14 ($\text{H}_{1'}$, dd).

- 50 -

F. 5'-Azido-2',5'-dideoxy-thymidine (7), Structure (IV) wherein R_{E1} is azido, R_{E2} is hydroxyl, and R_{E3} is H.

The synthesis of compound (7) was accomplished according to a procedure described by T. Lin, W. Prusoff, J. Med. Chem., 21, 109 (1978) from the commercially available pyrimidine thymidine (Aldrich Chemical Co., Milwaukee, WI).

G. Compound (8), Structure (IV) wherein R_{E1} is azido, R_{E2} is O-(t-butyl diphenylsilyl), and R_{E3} is H.

Compound (7) (3.0 g; 11.22×10^{-3} mole) is dissolved under argon in DMF (20 ml). Imidazole (1.3 g; 19.08×10^{-3} mole) and t-butyl diphenyl chlorosilane (4.627 g; 16.83×10^{-3} mole) are added. The mixture is stirred 48 hours at room temperature. The DMF is evaporated under reduced pressure and the residue is dissolved in CH_2Cl_2 (60 ml) and NaH_2PO_4 aq. (60 ml). The organic phase is washed with NaH_2PO_4 aq. (50 ml) and with brine (50 ml) and is dried over Na_2SO_4 . After evaporation of the solvent, the remaining material is chromatographed on silica gel ($CHCl_3$:MeOH 20:1). Compound (8) is obtained as a pale yellow oil (5.39 g; 10.66×10^{-3} mole; 95%). 1H -NMR ($CDCl_3$, 250 MHz, δ (ppm), J(Hz)): 1.95 ($H_{2'}$, ddd); 2.36 ($H_{2'}$, ddd); 6.38 ($H_{1'}$, dd).

H. Compound (9), Structure (IV) wherein R_{E1} is amino, R_{E2} is O-(t-butyl diphenylsilyl), and R_{E3} is H.

Compound (8) (7.3 g; 14.43×10^{-3} mole) is dissolved in degassed benzene (144 ml; 0.1 M; degassed with a stream of argon for 30 minutes). After addition of AIBN (0.237 g; 1.44×10^{-3} mole) and n-tributyltin hydride (9.244 g; 31.76×10^{-3} mole), the solution is heated at 80°C for 15 hours. An additional amount of AIBN (0.237 g; 1.44×10^{-3} mole) is introduced and the heating is continued for 5 hours. The solvent is evaporated and the residue is chromatographed on silica gel (Hexane:AcOEt 1:2). Compound (9) is obtained as a pale yellow solid (4.605 g; 9.6×10^{-3} mole; 85%). 1H -NMR ($CDCl_3$, 500 MHz, δ (ppm), J(Hz)): 1.93 ($H_{2'}$, ddd, $^2J = 13.5$, $^3J_{2',1'} = 6.8$, $^3J_{2',3'} = 6.8$); 2.35 ($H_{2'}$,

- 51 -

ddd, $^3J_{2',1'} = 6.2$, $^3J_{2',3'} = 4.2$); 3.87 ($H_{4'}$, ddd, $^3J_{3',4'} = 3.7$); 4.25 ($H_{3'}$, ddd); 6.31 ($H_{1'}$, dd).

I. Compound (10), Structure (III) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is (O-t-butyldiphenylsilyl), and
5 R_{E3} is H.

Compound (6) (0.468 g; $0.896 \cdot 10^{-3}$ mole) is dissolved in MeCN (30 ml). To this colorless solution are added N-methyl morpholine (0.099 g; $0.986 \cdot 10^{-3}$ mole), N-hydroxy benzotriazole (0.06 g; $0.448 \cdot 10^{-3}$ mole), O-(1H-N-hydroxy
10 benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (0.317 g; $0.986 \cdot 10^{-3}$ mole). The mixture is stirred 30 minutes at room temperature. Compound (9) (0.43 g; $0.896 \cdot 10^{-3}$ mole) then is dissolved in MeCN (5 ml) and is added with N-methyl morpholine (0.136 g; $1.344 \cdot 10^{-3}$
15 mole). After 20 hours at room temperature, the acetonitrile is evaporated under reduced pressure. The residue is dissolved in CH_2Cl_2 (60 ml) and NaH_2PO_4 (30 ml). The organic phase is washed with NaH_2PO_4 (2 x 30 ml) and with brine (2 x 30 ml). After drying over Na_2SO_4 , the
20 solvent is evaporated. The residue is chromatographed on silica gel (Hexane:AcOEt, 1:1). Compound (10) is obtained as a pale yellow solid (0.692 g; $0.703 \cdot 10^{-3}$ mole; 79%)
 1H -NMR ($CDCl_3$, 500 MHz, δ (ppm), J(Hz)): 5.79 ($H_{1'}$, dd, $^3J_{1',2'} = 7.0$); 6.20 ($H_{1'}$, dd, $^3J_{1',2'} = 6.4$); 6.95 (H_6 , q, $^4J = 1.0$);
25 7.27 (H_6 , q, $^4J = 1.0$). - MS (EI; m/e): 984 (M^+).

J. Compound (11), Structure (III) wherein R_{E1} is hydroxyl, R_{E2} is hydroxyl, and R_{E3} is H.

The compound (10) (0.68 g; $0.69 \cdot 10^{-3}$ mole) is dissolved under argon in THF (10 ml). Acetic acid (0.124
30 g; $2.07 \cdot 10^{-3}$ mole) and tetra-n-butyl ammonium fluoride (1.88 ml of a 1.1 M solution in THF; $2.07 \cdot 10^{-3}$ mole) are added. After 20 hours at room temperature, the mixture is coevaporated with toluene (3x) under reduced pressure. The residue is chromatographed on silica gel (AcOEt:MeOH,
35 20:1). Compound (11) is isolated as a white solid (0.295 g; $0.581 \cdot 10^{-3}$ mole; 84%). 1H -NMR ($DMSO-d_6$, 500 MHz, δ (ppm), J(Hz)): 5.95 ($H_{1'}$, dd, $^3J_{1',2'} = 6.2$, $^3J_{1',2'} = 4.0$); 6.22 ($H_{1'}$,

- 52 -

dd, $^3J_{1',2'} = 6.2$, $^3J_{1',2'} = 7.9$); 7.47 (H_6 , q, $^4J = 0.8$); 7.85 (H_6 , q, $^4J = 0.8$).

K. Compound (12), Structure (III) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is hydroxyl, and R_{E3} is H.

5 Compound (11) (0.29 g; 0.571×10^{-3} mole) is dissolved under argon in pyridine (10 ml). DMTC1 (4,4'-dimethoxy triphenylmethyl chloride; 0.194 g; 0.571×10^{-3} mole) is added. After 18 hours stirring at room temperature, an additional amount of DMTC1 (0.097 g; 0.285×10^{-3} mole) is
10 introduced. The reaction mixture is quenched with MeOH (1 ml) and after 40 hours is diluted with CH_2Cl_2 (50 ml) and Na_2CO_3 aq. (50 ml). The organic phase is washed with brine (2 x 30 ml) and dried over Na_2SO_4 . The solvent is coevaporated with toluene (3x) under reduced pressure. The
15 residue is chromatographed on silica gel (AcOEt:MeOH, gradient 50:1 \rightarrow 10:1 + 1% N-methyl morpholine). Compound (12) (0.426 g; 0.526×10^{-3} mole; 92%) is isolated as a pale yellow solid. 1H -NMR ($CDCl_3$, 500 MHz, δ (ppm)): 1.44 (Me, d); 1.88 (Me, d); 3.80 (2 x OMe, s); 7.66 (H_6 , q).

20 L. Compound (13), Structure (III) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(2-cyanoethyl- N,N,N',N'-tetraisopropyl phosphordiamidyl), and R_{E3} is H.

Compound (12) (0.413 g; 0.52×10^{-3} mole) is added under argon to a solution of
25 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidite (0.172 g; 0.572×10^{-3} mole) and N,N'-diisopropylammonium tetrazolide (0.107 g; 0.624×10^{-3} mole) in CH_2Cl_2 (20 ml). After 16 hours at room temperature, an additional amount of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidite
30 (0.172 g; 0.572×10^{-3} mole) is introduced. After 24 hours at room temperature, the mixture is quenched with $NaHCO_3$ aq. (20 ml). The organic phase is washed with brine (2 x 30 ml) and dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel
35 (Toluene:AcOEt, 1:1 + 1% N-methyl morpholine). Compound (13) (0.299 g; 0.296×10^{-3} mole; 57%) is isolated as a white

- 53 -

solid. ^{31}P -NMR (CDCl_3 , 101 MHz, δ (ppm)): 148.89 and 149.31.

EXAMPLE 22

Synthesis of Compound (17), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is C(O)OH, and R_{E3} is H.

- 5 A. Compound (14), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is styryl, and R_{E3} is H.

Compound (2) (3.558 g; 5.569×10^{-3} mole), prepared as in Example 21A, is dissolved under argon in degassed benzene (19 ml; 0.3 M; degassed with a stream of argon for
10 30 minutes). After addition of AIBN (0.183 g; 1.113×10^{-3} mole) and 1-phenyl 2-n-tributyltinethylene (21.90 g; 55.69×10^{-3} mole), the solution is heated at 80°C. AIBN (0.183 g; 1.113×10^{-3} mole) is added every 10 hour to a total of 0.915 g (5.566×10^{-3} mole). When no starting material is
15 remaining (as determined by thin-layer using chromatography silica gel, Hexane:AcOEt, 1:1) the solvent is evaporated and the residue is chromatographed on silica gel (gradient Hexane:AcOEt, 10:1 \rightarrow 4:1). Compound (14) is isolated as a white solid (2.367 g; 4.177×10^{-3} mole; 75%). ^1H -NMR (CDCl_3 ,
20 500 MHz, δ (ppm), J(Hz)): 2.34 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.0$, $^3\text{J}_{2',1'} = 3.0$, $^3\text{J}_{2',3'} = 8.2$), 2.46 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2',1'} = 7.1$, $^3\text{J}_{2',3'} = 10.2$); 3.28 ($\text{H}_{3'}$, m); 3.88 ($\text{H}_{4'}$, ddd, $^3\text{J}_{3',4'} = 9.1$); 6.21 ($\text{H}_{1'}$, dd); 7.58 (H_6 , q, $^4\text{J} = 1.0$).

- 25 B. Compound (15), Structure (IV) wherein R_{E1} is O-t-butyldiphenylsilyl, R_{E2} is formyl, and R_{E3} is H.

Derivative (14) (2.193 g ; 3.869×10^{-3} mole) is dissolved in a 2:1 mixture of dioxane: H_2O (30 ml). OsO_4 (0.098 g ; 0.386×10^{-3} mole) is added, followed by a solution of NaIO_4 (1.82 g ; 8.512×10^{-3} mole) in H_2O (8 ml). The
30 resulting suspension is stirred 3 hours at room temperature and extracted with CH_2Cl_2 (3 x 50 ml). The organic phase is washed with brine (2 x 30 ml) and dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel (Hexane:AcOEt, 1:1). Aldehyde (15) is
35 isolated as a white solid (1.334 g ; 2.708×10^{-3} mole; 70%). ^1H -NMR (CDCl_3 , 250 MHz, δ (ppm), J(Hz)): 2.26 ($\text{H}_{2'}$, ddd, $^2\text{J} =$

- 54 -

15.3, $^3J_{2',1'} = 6.1$, $^3J_{2',3'} = 9.4$); 2.77 ($H_{2'}$, ddd, $^3J_{2',1'} = ^3J_{2',3'}$, = 6.2); 3.36 ($H_{3'}$, m); 6x10 ($H_{1'}$, dd).

C. Compound (16), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is C(O)OCH₃, and R_{E3} is H.

5 Aldehyde (15) (1.091 g; 2.214×10^{-3} mole) is dissolved in DMF (10 ml). MeOH (0.425 g; 13.287×10^{-3} mole) and PDC (pyridinium dichromate; 4.998 g; 13.287×10^{-3} mole) are added. The resulting dark brown solution is stirred 20 hours at room temperature, diluted with CH₂Cl₂ (50 ml), and
10 washed with NaH₂PO₄ (2 x 50 ml) and with brine (2 x 50 ml). After drying over Na₂SO₄, the solvent is evaporated and the residue is chromatographed on silica gel (Hexane:AcOEt, 1:1). Compound (16) (0.661 g; 1.264×10^{-3} mole; 57%) is obtained as a white solid. ¹H-NMR (CDCl₃, 500 MHz, δ (ppm),
15 J(Hz)): 2.28 ($H_{2'}$, ddd, $^2J = 14.5$, $^3J_{2',1'} = 5.6$, $^3J_{2',3'} = 9.1$); 2.76 ($H_{2'}$, ddd, $^3J_{2',1'} = ^3J_{2',3'} = 6.9$); 3.42 ($H_{3'}$, ddd); 4.28 ($H_{4'}$, ddd, $^3J_{3',4'} = 7.0$); 6.21 ($H_{1'}$, dd).


D. Compound (17), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is C(O)OH, and R_{E3} is H.

20 Ester derivative (16) (2.2 g; 4.209×10^{-3} mole) is dissolved in a 1:1 mixture of THF-H₂O (50 ml). A solution of NaOH 0.1 N (126.3 ml; 12.627×10^{-3} mole) is added. After 16 hours of stirring at room temperature, the mixture is neutralized with HCl 1N, extracted with CH₂Cl₂ (2 x 50 ml).
25 The organic phase is washed with brine (2 x 50 ml) and dried over Na₂SO₄. After evaporation of the solvent, compound (17) is obtained as a white solid (2.015 g; 3.985×10^{-3} mole; 94%). ¹H-NMR (CDCl₃, 250 MHz, δ (ppm)); 6.22 ($H_{1'}$, dd).

- 55 -

EXAMPLE 23

Synthesis of Compound (26), Structure (V) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidyl), and R_{E3} is H.



(V)

A. Compound (18), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is hydroxyethyl, and R_{E3} is H.

Compound (4) (5.323 g; 10.5×10^{-3} mole), prepared as in Example 21C, is dissolved in MeOH (60 ml). NaBH_4 (1.192 g; 31.51×10^{-3} mole) is added portionwise at 0°C . When hydrogen evolution decreased, the reaction mixture was stirred at room temperature for 2 hours. NaH_2PO_4 aq. (20 ml) is added carefully. The MeOH is evaporated and the residue extracted with CH_2Cl_2 (2 x 50 ml). The organic phase is washed with brine (50 ml) and dried over Na_2SO_4 . The solvent is evaporated and the residue is chromatographed on silica gel (Hexane-AcOEt 1:1). Compound (18) is isolated as a white solid (5.01 g; 9.84×10^{-3} mole; 94%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.15 ($\text{H}_{2'}$, ddd, $^2J = 13.5$, $^3J_{2',1'} = 7.0$, $^3J_{2',3'} = 9.0$); 2.27 ($\text{H}_{2'}$, ddd, $^3J_{2',1'} = 4.0$, $^3J_{2',3'} = 8.0$); 2.49 ($\text{H}_{3'}$, m); 3.77 ($\text{H}_{4'}$, ddd); 6.11 ($\text{H}_{1'}$, dd).

- 56 -

B. Compound (19), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is ethoxy p-toluene sulfonyl, and R_{E3} is H.

Compound (18) (0.334 g; 0.656×10^{-3} mole) is dissolved under argon in $CHCl_3$ (15 ml). DMAP (0.241 g; 1.969×10^{-3} mole), pyridine (0.208 g; 2.626×10^{-3} mole), and tosylchloride (0.375 g; 1.969×10^{-3} mole) are added sequentially. After 24 hours of stirring at room temperature, additional amounts of reagents are introduced: DMAP (0.12 g; 0.984×10^{-3} mole); pyridine (0.102 g; 1.313×10^{-3} mole); tosyl chloride (0.187 g; 0.984×10^{-3} mole). The reaction mixture is diluted with CH_2Cl_2 (60 ml) after 40 hours and washed with NaH_2PO_4 aq. (2 x 50 ml) and with brine (2 x 50 ml). The organic phase is dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel (Hexane:AcOEt, 2:1). Compound (19) (0.369 g; 0.556×10^{-3} mole; 84%) is isolated as a pale yellow solid. 1H -NMR ($CDCl_3$, 250 MHz, δ (ppm): 2.44 (pMe-Ph-SO₃⁻, s).

C. Compound (20), having Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is azidoethyl, and R_{E3} is H.

Compound (19) (0.365 g; 0.55×10^{-3} mole) is dissolved in DMF (10 ml) under an atmosphere of dry argon. To this solution are added LiN_3 (0.135 g; 2.75×10^{-3} mole) and NaI (0.165 g; 1.1×10^{-3} mole). The mixture is heated at 100°C for 17 hours, then cooled to room temperature. Ether (100 ml) is added, then brine (50 ml). The organic phase is washed with brine (2 x 50 ml) and dried over Na_2SO_4 . After evaporation of the solvents under reduced pressure, the residue is chromatographed on silica gel (Hexane:AcOEt, 3:1). Compound (20) is isolated as a pale yellow oil (0.259 g; 0.485×10^{-3} mole; 88%). 1H -NMR ($CDCl_3$; 500 MHz, δ (ppm), J(Hz)): 2.13 ($H_{2'}$, ddd, $^2J = 13.5$, $^3J_{2',3'} = 8.7$, $^3J_{2',1'} = 7.0$); 2.26 ($H_{2'}$, ddd, $^3J_{2',3'} = 7.9$, $^3J_{2',1'} = 4.0$); 2.47 ($H_{3'}$, m); 3.73 ($H_{4'}$, ddd, $^3J_{4',3'} = 8.0$); 6.11 ($H_{1'}$, dd).

- 57 -

D. Compound (21), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is aminoethyl, and R_{E3} is H.

Azide derivative (20) (0.255 g ; 0.477×10^{-3} mole) is dissolved under argon in a degassed solution of benzene (0.1M: degassed with a stream of argon for 30 minutes; 5 ml). AIBN (0.008 g ; 0.047×10^{-3} mole) and n-tributyltin hydride (0.347 g ; 1.19×10^{-3} mole) are added at room temperature. The mixture is heated at 80°C for 5 hours. The solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel (gradient $\text{CHCl}_3:\text{MeOH}$, 50:1 \rightarrow 10:1). Compound (21) is isolated as a pale yellow oil (0.23 g ; 0.452×10^{-3} mole; 95%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.12 ($\text{H}_{2'}$, ddd, $^3J_{2',1'} = 6.9$); 2.24 ($\text{H}_{2'}$, ddd, $^3J_{2',1'} = 4.0$); 2.38 ($\text{H}_{3'}$, m); 3.74 ($\text{H}_{4'}$, ddd, $^3J_{3',4'} = 8.0$); 6.09 ($\text{H}_{1'}$, dd). MS(FD, m/e): 508 (M^+).

E. Compound (22), Structure (IV) wherein R_{E1} is C(O)OH, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

Compound (22) was prepared generally according to the procedures described in *Tetrahedron Letters*, 30(37): 4969-4972 (1989).

F. Compound (23), Structure (V) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H. Compound (22) (2.205 g ; 4.459×10^{-3} mole) is dissolved in MeCN (80 ml) and THF (10 ml). To this solution are added N-methyl morpholine (0.496 g ; 4.905×10^{-3} mole), N-hydroxy benzotriazole (0.301 g ; 2.229×10^{-3} mole), and O-(1H-N-hydroxy benzotriazole-1-yl) N,N,N',N'-tetramethyl uronium tetrafluoroborate (1.575 g ; 4.9×10^{-3} mole). The mixture is stirred 30 minutes at room temperature. Compound (21) (2.264 g ; 4.45×10^{-3} mole), dissolved in MeCN (20 ml), is added with N-methyl morpholine (0.676 g ; 6.688×10^{-3} mole). After 20 hours at room temperature, the solvents are evaporated under reduced pressure. The residue is dissolved in CH_2Cl_2 (100 ml) and NaH_2PO_4 aq. (50 ml). The organic phase is washed with NaH_2PO_4 (2 x 50 ml) and with brine (2 x 50 ml) and dried over Na_2SO_4 . The solvent is evaporated and the residue is

chromatographed on silica gel (Hexane:AcOEt, 1:2).

Compound (23) is isolated as a white solid (4.11 g; 4.175×10^{-3} mole; 93%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J (Hz)): 2.34 ($\text{H}_{2'}$, ddd, $^2J = 14.3$, $^3J_{2'-3'} = 4.3$, $^3J_{2'-1'} = 9.9$); 4.01 (H_5 , m); 4.28 (H_4 , s); 4.55 (H_3 , d); 6.07 ($\text{H}_{1'}$, dd, $^3J_{1'-2'} = 6.5$, $^3J_{1'-2'} = 3.8$); 6.17 ($\text{H}_{1'}$, dd, $^3J_{1'-2'} = 5.0$). MS (CI; m/e): 984 M^+ .

G. Compound (24), Structure (V) wherein $\text{R}_{\text{E}1}$ is hydroxyl, $\text{R}_{\text{E}2}$ is hydroxyl, and $\text{R}_{\text{E}3}$ is H.

Compound (23) (1.292 g; 1.312×10^{-3} mole) is dissolved under argon in THF (30 ml). Acetic acid (0.236 g; 3.937×10^{-3} mole) and tetra-*n*-butylammonium fluoride (3.58 ml of a 1.1 M solution in THF; 3.937×10^{-3} mole) are added. After 24 hours at room temperature, the mixture is coevaporated with toluene (3x) under reduced pressure. The residue is chromatographed on silica gel (AcOEt:MeOH, 20:1). Compound (24) is isolated as a white solid (0.647 g; 1.27×10^{-3} mole; 97%). $^1\text{H-NMR}$ (CD_3OD , 500 MHz, δ (ppm), J (Hz)): 4.25 (H_4 , d, $^3J_{4'-3'} = 1.9$); 6.05 ($\text{H}_{1'}$, dd, $^3J_{1'-2'} = 2.1$, $^3J_{1'-2'} = 7.8$); 6.21 ($\text{H}_{1'}$, dd, $^3J_{1'-2'} = 5.9$, $^3J_{1'-2'} = 8.4$); 7.88 (H_6 , q); 8.03 (H_6 , q).

H. Compound (25), Structure (V) wherein $\text{R}_{\text{E}1}$ is *O*-(dimethoxytrityl), $\text{R}_{\text{E}2}$ is hydroxyl, and $\text{R}_{\text{E}3}$ is H.

Compound (24) (0.64 g; 1.261×10^{-3} mole) is dissolved under argon in pyridine (10 ml). DMTC1 (4,4'-dimethoxytriphenylmethyl chloride; 0.428 g; 1.263×10^{-3} mole) is added. After 17 hours stirring at room temperature, an additional amount of DMTC1 (0.428 g; 1.263×10^{-3} mole) is introduced. The reaction mixture is quenched with MeOH (1 ml) after 40 hours and diluted with CH_2Cl_2 (60 ml) and Na_2CO_3 aq. (50 ml). The organic phase is washed with brine (2 x 30 ml) and dried over Na_2SO_4 . The solvent is coevaporated with toluene (3 x) under reduced pressure. The residue is chromatographed on silica gel (AcOEt:MeOH, gradient 50:1 \rightarrow 10:1 + 1% *N*-methyl morpholine). Compound (25) (0.902 g; 1.11×10^{-3} mole; 88%) is isolated as a white solid. $^1\text{H-NMR}$ (CD_3OD , 500 MHz, δ (ppm), J (Hz)): 4.23 (H_4 , d, $^3J_{4'-3'}$,

- 59 -

= 1.8); 6.06 ($H_{1'}$, dd, $^3J_{1'-2'} = 2.4$, $^3J_{1'-2'} = 7.5$); 6.19 ($H_{1'}$, dd, $^3J_{1'-2'} = 5.9$, $^3J_{1'-2'} = 9.0$). MS(CI: m/e): 809 (M+).

I. Compound (26), Structure (V) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidyl), and R_{E3} is H.

Compound (25) (0.89g; 1.121×10^{-3} mole) is added under argon to a solution of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidite (0.371 g; 1.233×10^{-3} mole) and of N,N'-diisopropylammonium tetrazolide (0.23 g; 1.345×10^{-3} mole) in CH_2Cl_2 (30 ml). After 18 hours at room temperature, an additional amount of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphordiamidite (0.371 g; 1.233×10^{-3} mole) is introduced. After 24 hours at room temperature, the mixture is quenched with $NaHCO_3$ aq. (20 ml). The organic phase is washed with brine (2 x 30 ml) and dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel (hexane:AcOEt, 1:2 + 1% N-methyl morpholine). Compound (26) is isolated as a pale yellow solid (0.624 g; 0.617×10^{-3} mole; 55%). ^{31}P -NMR ($CDCl_3$, 101 MHz, δ (ppm)): 148.17 and 150.57.

EXAMPLE 24

Synthesis of Compound (30), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is aminomethyl, and R_{E3} is H.

A. Compound (27), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is hydroxymethyl, and R_{E3} is H.

Aldehyde (15) (0.759 g; 1.541×10^{-3} mole), prepared as described in Example 22A-B, is dissolved under argon in MeOH (6 ml). The solution is cooled to 0°C and $NaBH_4$ (0.291 g; 7.708×10^{-3} mole) is added. After 30 minutes at this temperature, the mixture is stirred at 25°C for 20 hours. To this solution is added NaH_2PO_4 aq. (30 ml). The MeOH is evaporated under reduced pressure and the aqueous phase is extracted with CH_2Cl_2 (3 x 30 ml). The organic phase is washed with brine (2 x 20 ml) and dried over Na_2SO_4 . After removal of the solvent, the residue is chromatographed on silica gel (Hexane:AcOEt, 1:2). Compound (27) is isolated

- 60 -

as a white solid (0.381 g; 0.77×10^{-3} mole; 50%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.14 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.0$, $^3\text{J}_{2'-1'} = 5.2$, $^3\text{J}_{2'-3'} = 8.8$); 2.29 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2'-1'} = 6.8$, $^3\text{J}_{2'-3'} = 5.9$); 2.60 ($\text{H}_{3'}$, m); 3.94 ($\text{H}_{4'}$, ddd); 6.13 ($\text{H}_{1'}$, dd).

5 MS(FD, m/e): 495 (M^+).

B. Compound (28), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is methoxy p-toluene sulfonyl, and $\text{R}_{\text{E}3}$ is H.

Compound (27) (0.397 g ; 0.802×10^{-3} mole) is dissolved under argon in CHCl_3 (15 ml). To this solution, cooled at 0°C , are added pyridine (0.254 g ; 3.21×10^{-3} mole); DMAP (0.294 g ; 2.407×10^{-3} mole), and tosylchloride (0.459 g ; 2.407×10^{-3} mole). After 10 minutes at 0°C , the mixture is stirred at room temperature. Analytical thin-layer chromatography (Hexane:AcOEt, 1:1) reveals that some starting material remains. Therefore, adds tosyl chloride (0.306 g ; 1.6×10^{-3} mole), pyridine (0.127 g ; 1.605×10^{-3} mole), and DMAP (0.196 g ; 1.6×10^{-3} mole) were added. After 40 hours, this solution is diluted with CHCl_3 (50 ml), washed with NaH_2PO_4 aq. (2 x 40 ml), with NaHCO_3 aq. (2 x 40 ml), and with brine (2 x 40 ml), and dried over Na_2SO_4 . After evaporation of the solvent under reduced pressure, the residue is chromatographed on silica gel (Hexane:AcOEt, 2:1). Compound (28) is isolated as a colorless solid (0.429 g ; 0.661×10^{-3} mole; 82%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.14 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.8$, $^3\text{J}_{2'-1'} = 5.6$, $^3\text{J}_{2'-3'} = 9.0$); 2.22 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2'-1'} = 6.8$, $^3\text{J}_{2'-3'} = 6.8$); 2.84 ($\text{H}_{3'}$, m); 3.85 ($\text{H}_{4'}$, ddd, $^3\text{J}_{3'-4'} = 7.0$); 6.05 ($\text{H}_{1'}$, dd). MS(FD, m/e): 649 (M^+).

30 C. Compound (29), Structure (IV) wherein $\text{R}_{\text{E}1}$ is O-(t-butyldiphenylsilyl), $\text{R}_{\text{E}2}$ is azidomethyl, and $\text{R}_{\text{E}3}$ is H.

Tosyl derivative (28) (0.425 g ; 0.655×10^{-3} mole) is dissolved under argon in DMF (15 ml). To this solution are added LiN_3 (0.16 g ; 3.275×10^{-3} mole) and NaI (0.196 g ; 1.31×10^{-3} mole) at room temperature. The mixture is stirred for 20 hours at 100°C . The reaction is followed by analytical thin-layer chromatography (hexane:AcOEt, 1:3).

- 61 -

When the reaction is finished, ether is added (100 ml). This solution is washed with brine (3 x 50 ml) and dried over Na_2SO_4 . After filtration, the residue is chromatographed on silica gel (Hexane:AcOEt, 2:1). Azide derivative (29) is obtained as a colorless glass (0.262 g; 0.504×10^{-3} mole; 77%). $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, δ (ppm), J(Hz)): 2.18 ($\text{H}_{2'}$, ddd, $^2\text{J} = 14.3$, $^3\text{J}_{2',3} = 8.9$, $^3\text{J}_{2',1'} = 5.5$); 2.28 ($\text{H}_{2'}$, ddd, $^3\text{J}_{2',3} = ^3\text{J}_{2',1'} = 6.5$); 2.67 (H_3 , m); 3.37 ($\text{CH}_2\text{-N}_3$, d, $^3\text{J} = 6.3$); 7.46 (H_6 , q, $^4\text{J} = 1.0$). MS(FD, m/e): 520 (M^+).


D. Compound (30), Structure (IV) wherein R_{E1} is O-(t-butyldiphenylsilyl), R_{E2} is aminomethyl, and R_{E3} is H.

Azide derivative (29) (0.245 g; 0.471×10^{-3} mole) is dissolved under argon in a degassed solution of benzene (0.1 M: degassed with a stream of argon for 30 minutes). AIBN (0.008 g; 0.0471×10^{-3} mole) and nBu_3SnH (n-tributyltin hydride; 0.343 g; 1.178×10^{-3} mole) are added at room temperature. The mixture is heated at 80°C during 7 hours. Analytical thin layer chromatography (Hexane:AcOEt, 1:1) reveals that some starting material is still present in the reaction mixture. Therefore, AIBN is added (0.008 g; 0.0471×10^{-3} mole). The reaction mixture is heated for an additional 17 hours at 80°C . The solvent is evaporated under reduced pressure. The residue (pale yellow oil) is chromatographed on silica gel (flash-chromatography; gradient AcOEt:MeOH, 50:1 \rightarrow 20:1 \rightarrow 10:1 containing 1% of NEt_3). Amine (30) is isolated as a white powder (0.196 g; 0.397×10^{-3} mole; 84%). $^1\text{H-NMR}$ (CD_3OD , 500 MHz, δ (ppm), J(Hz)): 2.28 ($2\text{H}_{2'}$, m); 2.58 (H_3 , m); 2.70 ($\text{C}_3\text{-CH}_2\text{-NH}_2$, dd, $^2\text{J} = 12.2$, $^3\text{J} = 8.0$); 2.82 ($\text{C}_3\text{-CH}_2\text{-NH}_2$, dd, $^3\text{J} = 5.4$); 6.11 ($\text{H}_{1'}$, dd, $^3\text{J} = 5.9$); 7.54 (H_6 , q, $^4\text{J} = 1.1$). MS (FD, m/e): 494 (M^+).

- 62 -

EXAMPLE 25

Synthesis of Compound (42), Structure (VI) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidyl), and R_{E3} is H.



(VI)

A. Compound (31), Structure (IV) wherein R_{E1} is hydroxyl, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

Compound (31) was prepared generally in accordance with the methods described in *Tetrahedron Letters*, 23(26): 2641-2644 (1982).

B. Compound (32), Structure (IV) wherein R_{E1} is hydroxyl, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is $\text{CH}_2\text{OCH}_2\text{Ph}$.

To a stirred solution of (31) (3.53 g, 7.4 mmol) in 15 ml of dry acetonitrile at room temperature under argon was added DBU (2.2 ml, 14.8 mmol) followed by benzylchloromethylether (2.0 g, 12.8 mmol). After 4 hours at room temperature, the reaction was diluted with 150 ml of CH_2Cl_2 , and the organic phase was washed with two 25 ml portions of a 10% aqueous KHSO_4 , one 70 ml portion of H_2O and one 50 ml portion of brine. After drying over Na_2SO_4 , the organic phase was concentrated under reduced pressure. Chromatography of the residue on silica gel (gradient

- 63 -

Hexane:AcOEt) afforded the protected thymidine (32) as a white foam (3.21 g, 73%). ¹H NMR (CDCl₃, 300 MHz) δ: 1.01 (9H, s, 3'-O'-SitBu), 1.79 (3H, s, Me-5), 4.61 (2H, s, O-CH₂-Ph), 5.40 (2H, s, -N-CH₂-O).

5 C. Compound (33), Structure (V) wherein R_{E1} is CH=CHC(O)OCH₃, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is CH₂OCH₂Ph.

To a stirred solution of oxalyl chloride (0.65 ml, 7.3 mmol) in 25 ml of dry CH₂Cl₂ at -78°C under argon was added a solution of dry DMSO (1.05 ml, 14.6 mmol) in 5 ml of CH₂Cl₂. The addition was performed over 5 minutes. The resultant mixture was stirred for 1 hour at -78°C and a solution of compound (32) (2.91 g, 4.84 mmol) in 25 ml of CH₂Cl₂ was added over 10 minutes. After 1 h at -78°C, dry triethylamine (4.1 ml, 29.2 mmol) was added and the reaction mixture was allowed to warm to 0°C.

Methoxycarbonyl methylene triphenylphosphorane (2.45 g, 7.2 mmol) was added as a solid and the reaction was stirred at room temperature for 2 hours. A 200 ml portion of CH₂Cl₂ was added, followed by 50 ml of H₂O. The resulting mixture was stirred 10 minutes and the layers were separated. The organic layer was washed with two 50 ml portions of H₂O and one 50 ml portion of brine. The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure.

25 Chromatography of the residue on silica gel (4:1 hexane/ethyl acetate) afforded α,β-unsaturated methylester (33) (2.95 g; 93%). ¹H NMR (CDCl₃, 300 MHz) δ: 0.875 (9H, s, 3'-OSitBu); 5.66 (1H, dd, J = 16 Hz, J = 1.5 Hz, H-6'), 6.45 (1H, dd, J = 7 Hz, H-1'), 6.41 (1H, dd, J = 16 Hz and J = 6 Hz).

D. Compound (34), Structure (IV) wherein R_{E1} is CH₂CH₂C(O)OCH₃, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

A vigorously stirred solution of (33) (2.7 g, 4.1 mmol) in 85 ml of MeOH was hydrogenated under hydrogen (atmospheric pressure) at room temperature in the presence of powdered Pd/C 10% (960 mg) for 3 days. The reaction mixture was filtered through a path of SiO₂, and the filter

- 64 -

cake was washed with MeOH (~100 ml). Concentration of the filtrate under reduced pressure afforded crude (34) (2.1 g, 95%) as an colorless foam. This material was used for the next step without further purification. ¹H-NMR (CDCl₃, 300 MHz) δ: 1.82 (3H, s, Me-5), 3.56 (3H, s, OMe), 6.25 (1H, dd, J = 6 Hz, H-1'), 6.92 (1H, s, H-6), 8.6 (1H, s broad, N-H).

E. Compound (35), Structure (IV) wherein R_{E1} is CH₂C(O)OH, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

To a solution of the crude compound (34) (2.1 g, 3.9 mmol) in MeOH (10 ml) at room temperature, was added 40 ml of a 2M solution of KOH in MeOH/H₂O (7:3). After 2 hours at room temperature, the solution was acidified to pH 4 with Dowex 50W x 4 (Fluka). The suspension then was filtered and the solid washed with 150 ml of CH₂Cl₂ and 50 ml H₂O. The layers were separated. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were washed with 50 ml portions of H₂O and brine. The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to give acid (34) (1.27 g, 84%) as a white powder. ¹H NMR (CDCl₃, 300 MHz) δ: 1.82 (3H, s; Me-5) 3.9 (1H, m, H-4'), 6.25 (1H, s, H-1') 6.95 (1H, s, H-6).

F. Compound (36), Structure (IV) wherein R_{E1} is O-(trityl), R_{E2} is azido, and R_{E3} is H.

Compound (36) was prepared generally according to the procedures described in Lin, T. and W. Prusoff, *J. Med. Chem.* 21: 109 (1978).

G. Compound (37), Structure (IV) wherein R_{E1} is O-(trityl), R_{E2} is amino, and R_{E3} is H.

A 10.5 g (0.02 Mol) portion of azide (36) is dissolved in 100 ml dioxane. After the addition of 0.5 g of 10% Pd/C, hydrogenation is carried out under atmospheric pressure at 25°C. Filtration after 16 h and evaporation under reduced pressure afforded the crude amine, which was crystallized with CH₂Cl₂/Et₂O. Yield 7.0 g of amino derivative (37). ¹H-NMR (DMSO-d₆): 1.50 (s, 3H, CH₃); 6.15 (m, 1H, H(1')); 7.50 (s, 1H, H(6)).

H. Compound (38), Structure (VI) wherein R_{E1} is O-(trityl), R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H. (38)

To a stirred mixture of (35) (313 mg, 0.6 mmol) and amine (37) (289 mg, 0.6 mmol) in 5 ml of dry CH_2Cl_2 under argon at room temperature was added N,N'-dicyclohexylcarbodiimide (144 mg, 0.7 mmol) and DMAP (30 mg, 0.25 mmol). After 12 hours at room temperature, the mixture was diluted with 100 ml of CH_2Cl_2 and was washed with 20 ml of 0.1 N HCl, 3 x 20 ml of H_2O and 2 x 20 ml of brine. The organic layer was dried over Na_2SO_4 and concentrated under reduced pressure to furnish an oil (0.95 g), which was chromatographed on silica gel (98:2 chloroform; methanol) to afford dimer (38) (0.46 g, 78%) as a white foam. 1H NMR ($CDCl_3$, 300 MHz) δ : 1.32 and 1.80 (3H, s, Me-5), 5.96 and 6.25 (1H, dd, $J = 6$ Hz, H-1'), 6.52 (1H, d, $J = 6$ Hz, N-H (chain)), 6.9 and 7.5 (1H, s, H-6) 9.18 and 9.37 (1H, s broad, N3-H).

I. Compound (39), Structure (VI) wherein R_{E1} is hydroxyl, R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

A solution of (38) (1.01 g, 1.02 mmol) in a mixture of acetic acid (1.6 ml) and water (0.4 ml) was heated at 80°C for 1 hour 30 minutes. The solvent then was removed under reduced pressure and the residue was chromatographed on silica gel (CH_2Cl_2 /MeOH/ Et_3N , 95:4:1) to afford (39) (591 mg, 78%) as a white foam. 1H -NMR ($CDCl_3$, 300 MHz) δ : 1.76 and 1.82 (3H, s, Me-5), 6.02 and 6.10 (1H, dd, $J = 6$ Hz, H-1') 6.9 and 7.6 (1H, 1s, H-6), 7.05 (1H, d broad, NH (chain)), 9.82 and 9.92 (1H, s broad, N3-H).

J. Compound (40), Structure (VI) wherein R_{E1} is O-(dimethoxytrityl), R_{E2} is O-(t-butyldiphenylsilyl), and R_{E3} is H.

To a solution of (39) (860 mg, 1.15 mmol) in 20 ml of CH_2Cl_2 at room temperature under argon was added DMAP (210 mg, 1.7 mmol) and Et_3N (0.5 ml, 3.5 mmol), followed by dimethoxytrityl chloride (575 mg, 1.7 mmol). After stirring for 12 hours at room temperature, more dimethoxytrityl chloride (300 mg, 8.8 mmol) was added.

- 66 -

- After 24 hours at room temperature, the reaction mixture was diluted with CH_2Cl_2 (~100 ml) and was washed with brine. The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure to give an oil, which was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{Et}_3\text{N}$ 94:5:1) to afford (40) (575 mg, 48%). ^1H NMR (CDCl_3 ; 300 MHz) δ : 1.46 and 1.92 (3H, s, Me-5), 3.88 (6H, s, OMe), 6.13 and 6.4 (1H, s, H-1'), 7.07 (1H, s, H6) 9.5 and 9.6 (1H, s broad, $\text{N}_3\text{-H}$).
- 10 K. Compound (41), Structure (VI) wherein $\text{R}_{\text{E}1}$ is O-(dimethoxytrityl), $\text{R}_{\text{E}2}$ is hydroxyl, and $\text{R}_{\text{E}3}$ is H.
- To a solution of (40) (405 mg, 0.39 mmol) in 3 ml of THF at room temperature was added tetra-n-butylammonium fluoride (141 mg, 0.5 mmol) at once as a solid. After 3 hours at room temperature, the solvent was removed under reduced pressure and the residues was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{Et}_3\text{N}/\text{methanol}$, 93:1:6) to afford (41) (310 mg, 100%) as a white foam. ^1H NMR (CDCl_3 , 300 MHz) δ : 1.21 and 1.73 (3H, s, Me-5), 3.64 (6H, s, OMe), 6.00 and 6.22 (3H, dd, $\text{J} = 6 \text{ Hz}$, H-1'), 7.25 and 7.55 (1H, s, H-6).
- 20 L. Compound (42), Structure (VI) wherein $\text{R}_{\text{E}1}$ is O-(dimethoxytrityl), $\text{R}_{\text{E}2}$ is O-(2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidyl), and $\text{R}_{\text{E}3}$ is H.
- 25 To a stirred solution of (41) (310 mg, 0.39 mmol) in 5 ml of dry CH_2Cl_2 containing diisopropylammonium tetrazolide (55 mg, 0.32 mmol) under argon at room temperature was added the 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoradiazamidite (0.180 ml, 0.6 mmol).
- 30 After 13 hours at room temperature, the reaction mixture was diluted with 100 ml of CH_2Cl_2 , washed with 5% aqueous solution of NaHCO_3 , H_2O and brine. After drying over Na_2SO_4 , the solvent was removed under reduced pressure. The crude oil was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{N-methyl morpholine}/\text{methanol}$ 98:1:1) to afford (42) (285 mg, 74%) [which was coevaporated 3 times with 150 ml

of d
MHz)EXAM
Synt
5 C(O)

amin

with

10
aminmmol
temp

15 t-bu

resu

and

t-bu

hour

20 mmHg

(CH₂

foam

0.81

s, p

25 m, p

H-1'

CH=C

30 mmol

a s

ove

of

wit

35 min

add

of dry benzene to give a white foam]. ^{31}P NMR (CDCl_3 , 100 MHz) δ : 148.658 and 148.070 ppm.

EXAMPLE 26

Synthesis of Compound (48), Structure (IV) wherein R_{E1} is C(O)OH, R_{E2} is O-(t-butyldimethylsilyl), and R_{E3} is H.

A. Compound (43), Structure (IV) wherein R_{E1} is aminomethyl, R_{E2} is hydroxyl, and R_{E3} is H.

Compound (43) was prepared generally in accordance with the procedures described in *Chem. Comm.* p. 422 (1968).

10 B. Compound (44), Structure (IV) wherein R_{E1} is aminomethyl, R_{E2} is O-(t-butyldimethylsilyl), and R_{E3} is H.

To a mixture of crude aminoalcohol (43) (1.40 g, 5.5 mmol) in dry DMF 10 ml and dry CH_2Cl_2 5 ml was added at room temperature under argon, imidazole (520 mg, 7.6 mmol) and
15 t-butyl dimethylchlorosilane (1.08 g, 7.2 mmol). The resulting mixture was stirred 8 hours at room temperature and more reagents were added: imidazole (210 mg, 3.1 mmol); t-butyldimethylchlorosilane (420 mg, 2.8 mmol). After 22
20 hours, the solvents were removed under high vacuum (~10-2 mmHg, 45°C). The crude solid was purified on Silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{Et}_3\text{N}$) to give (44) (1.70 g, 83%) as pale yellow foam. ^1H NMR (CDCl_3 ; 300 MHz) δ : 0.00 (6H, s, 3'-OSiMe₂); 0.81 (9H, s, 3'-O'SitButyl); 1.75 (2H, m, H-5'); 1.97 (3H, s, Me-T); 2.15 (2H, m, H-2'); 3.40 (2H, m, H-6'); 3.74 (1H, m, H-4'); 4.05 (1H, m, H-3'); 6.07 (1H, t, J = 6.5 Hz; H-1'); 7.06 (1H, s, H-6), 8.10 (1H, s, N-H).

C. Compound (45), Structure (IV) wherein R_{E1} is $\text{CH}=\text{CH}_2$, R_{E2} is O-(t-butyldimethylsilyl), and R_{E3} is $\text{CH}_2\text{OCH}_2\text{Ph}$.

To a stirred solution of oxalyl chloride (2.2 ml, 25
30 mmol) in 45 ml of dry CH_2Cl_2 at -78°C under argon was added a solution of dry DMSO (3.6 ml, 50 mmol) in 15 ml of CH_2Cl_2 over 5 min. After stirring for 1 hour at -78°C, a solution of compound (32) (10 g, 10.64 mmol), prepared in accordance with examples 25A-B, in 50 ml of CH_2Cl_2 was added. After 45
35 min. at -78°C, dry triethylamine (14.8 ml, 0.1 mol) was added over 5 min and the reaction mixture was allowed to

- 68 -

warm to -30°C over 1 hour. To the latter solution at -78°C was added a solution of methylene triphenylphosphorane, prepared by addition of 1.6N n-butyl lithium in hexane (62.5 ml, 0.1 mol) to a stirred slurry solution of methyl-
5 triphenylphosphonium bromide (35.7 g, 0.1 mol) in 150 ml of dry THF at -78°C , followed by stirring at RT for 2 hours. The resulting mixture was allowed to warm to RT and was stirred 2 hours. Then 100 ml H_2O was added and the mixture concentrated under reduced pressure to about 150 ml
10 whereupon it was diluted with 300 ml ether. The organic layer was washed with water and brine and was dried over sodium sulfate. Removal of the solvent gave an oil which was purified by chromatography on silica (hexane-ethyl acetate 4:1) to afford compound (45) (3.55 g, 35%). $^1\text{H NMR}$
15 (CDCl_3 ; 300 MHz) δ : 1.02 (9H, s, 3'-OSitBu); 1.80 (3H, s, Me-5); 4.62 (2H, s, Ph- CH_2 -O); 5.5 (1H, m, H-5'); 6.32 (1H, dd, $J=6.0$ Hz, H-1'); 6.95 (1H, s, H-8).

D. Compound (46), Structure (IV) wherein $\text{R}_{\text{E}1}$ is hydroxymethyl, $\text{R}_{\text{E}2}$ is O-(t-butyldimethylsilyl), and $\text{R}_{\text{E}3}$ is
20 $\text{CH}_2\text{OCH}_2\text{Ph}$.

To a stirred solution of compound (45) (252 mg, 0.42 mmol) in 5 ml of dry THF, cooled to 0°C under an argon atmosphere, was added 0.25 ml (2.5 mmol) of 10M borane dimethyl sulphide complex in THF. After 2 hours at 0°C ,
25 the mixture was quenched by the slow continuous concurrent addition of 4 ml of 2N aqueous NaOH solution and 1 ml of 30% aqueous H_2O_2 solution. The reaction mixture was allowed to warm to room temperature for 10 minutes, diluted with 50 ml of CH_2Cl_2 , and washed with H_2O and brine. After being
30 dried (MgSO_4), the organic phase was concentrated under reduced pressure. Chromatography of the residue on silica gel (hexane-ethyl acetate, 2:1 to 1:1) afforded compound (46) (186 mg, 72%) as a colorless oil. $^1\text{H NMR}$ (CDCl_3 , 300 MHz) δ : 1.01 (9H, s, 3'-OSitBu), 1.80 (3H, s, Me-5), 3.51
35 (2H, m, CH_2 -6'), 5.41 (2H, s, O- CH_2 -N), 6.27 (1H, dd, $J = 6$ Hz, H-1'), 6.87 (1H, s, H-6).

E. Compound (46), Structure (IV) wherein R_{E1} is hydroxymethyl, R_{E2} is O-(t-butyldimethylsilyl), and R_{E3} is H.

A vigorously stirred solution of compound (46) (1.03 g, 1.67 mmol) in 37 ml of MeOH was hydrogenated (atmospheric pressure) at room temperature in the presence of powdered Pd/C 10% (520 mg) for 3 days. The reaction mixture was filtered through a path of silica gel. The solid was washed with MeOH (100 ml). To the filtrate was added KOH (~200 mg, 3.6 mmol), and the resulting solution was stirred for 1 hour at room temperature. The solution was concentrated under reduced pressure to approximately 20 ml and was diluted with CH_2Cl_2 (100 ml) and the organic phase was washed with H_2O and brine. After being dried ($MgSO_4$), the solvent was removed under reduced pressure to give compound (47) (742 mg, 90%). This material was used for the next step without further purification. 1H NMR ($CDCl_3$ -300 MHz) δ : 0.94 (9H, s, 3'-OSitBu), 1.73 (s, 3H, Me-5), 3.45 (2H, m, CH_2 -6'), 6.17 (1H, dd, J = 6.5 Hz, H-1'), 6.85 (1H, s, H6).

F. Compound (48), Structure (IV) wherein R_{E1} is C(O)OH, R_{E2} is O-(t-butyldimethylsilyl), and R_{E3} is H.

To a vigorously stirred solution of compound (47) (710 mg, 1.5 mmol) in 5 ml of dry DMF at room temperature under argon was added the pyridinium dichromate (PDC) (1.5 g, 4 mmol). After 14 hours the brown solution was diluted with 35 ml of EtOAc and stirred 5 min. The suspension was filtered through a path of silica gel and the solid was washed with 75 ml of EtOAc. Removal of the solvents and chromatography of the residue on silica gel (ethyl acetate-methanol 95:5) afforded acid (48). 1H NMR ($CDCl_3$, 300 MHz) δ : 1.09 (9H, s, 3'-O-SitBu), 1.83 (3H, s, Me-5), 2.38 (2H, m, CH_2 -5'), 6.32 (1H, dd, J = 6.5 Hz, H-1'), 7.23 (1H, s, H-6).

- 70 -

EXAMPLE 27

Synthesis of (50), Structure (IV) wherein R_{E1} is $CH_2C(O)CH_3$, R_{E2} is O-t-butyltrimethylsilyl, and R_{E3} is CH_2OCH_2Ph .

A. Compound (49), Structure (IV) wherein R_{E1} is $CH=(1,3-dithian-2-yl)$, R_{E2} is O-(t-butyltrimethylsilyl), and R_{E3} is CH_2OCH_2Ph .

To a stirred solution of oxalyl chloride (2.2 ml, 25 mmol) in 45 ml of dry CH_2Cl_2 at $-78^\circ C$ under argon was added a solution of dry DMSO (3.6 ml, 50 mmol) in 15 ml of CH_2Cl_2 over 5 minutes. After stirring for 1 hour at $-78^\circ C$, a solution of compound (32) (10 g, 10.64 mmol) in 50 ml of CH_2Cl_2 was added over 20 minutes. After 45 minutes at $-78^\circ C$, dry triethylamine (14.8 ml, 0.1 mol) was added over 5 minutes and the reaction mixture was allowed to warm to $-30^\circ C$ over 1 hour. To the latter solution at $-78^\circ C$ was added a solution of phosphonium ylide [prepared by addition of 0.5N potassium bis(trimethylsilyl)amide in toluene (85 ml, 42.2 mmol) to a stirred slurry solution of 1,3-dithian-2-yl-triphenylphosphonium chloride (16g, 38.4 mmol) in 135 ml of dry THF at $-78^\circ C$, followed by stirring at room temperature for 3 hours]. The resulting mixture was allowed to warm to room temperature and was stirred 2 hours. Then, 300 ml of CH_2Cl_2 and 100 ml of H_2O were added. The mixture was stirred 10 minutes and the layers were separated. The aqueous layer was extracted with one 200 ml portion of CH_2Cl_2 . The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (hexane-EtOAc) to give compound (49) (10.1 g, 87%), MS(FD; m/e): 701 (M^+).

B. Compound (50), Structure (IV) wherein R_{E1} is $CH_2C(O)OCH_3$, R_{E2} is O-(t-butyltrimethylsilyl), and R_{E3} is CH_2OCH_2Ph .

To a stirred solution of (49) (1.3 g, 1.85 mmol) in MeOH: H_2O (9:1; 50 ml) at reflux under argon was added mercuric chloride (2.9 g, 10.7 mmol). After 40 minutes, the reaction mixture was cooled to room temperature, the

- 71 -

salts were filtered, the mother liquor was concentrated under reduced pressure, and the residue was diluted with 100 ml of CH_2Cl_2 . The organic layer was washed with two 30 ml portions of H_2O and one portion of brine. After drying over MgSO_4 , the solvent was removed and the residue was purified by chromatography on silica gel (hexane-ethyl acetate, 7:3) to afford compound (50). ^1H NMR (CDCl_3 , 300 MHz) δ : 1.02 (9H, s, 3'-OSitBu), 1.80 (3H, s, Me-5), 2.28 (2H, m, CH_2 -5'), 3.52 (3H, s, MeO), 5.41 (2H, s, O- CH_2 -N), 6.29 (1H, dd, $J=6.5$ Hz, H-1'), 7.03 (1H, H-6).

- 72 -

EVALUATION**PROCEDURE 1 - Hybridization Analysis.**

The relative ability of an oligonucleotide, an oligonucleotide analog or oligonucleoside of the invention to bind to complementary nucleic acids can be compared by determining the melting temperature of a particular hybridization complex. The melting temperature (T_m), a characteristic physical property of double standard RNA, denotes the temperature in degrees centigrade at which 50% helical versus coil (unhybridized) forms are present. T_m is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher T_m . The higher the T_m , the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the T_m . Consequently, absolute fidelity of base pairing is necessary to have optimal binding of an antisense oligonucleotide or oligonucleoside to its targeted RNA.

A. Evaluation of the thermodynamics of hybridization of oligonucleotide analogs.

The ability of the oligonucleotide analogs of the invention to hybridize to their complementary RNA or DNA sequences can be determined by thermal melting analysis. The RNA complement is synthesized from T7 RNA polymerase and a template-promoter of DNA synthesized with an Applied Biosystems, Inc. 380B nucleic acid synthesizer. The RNA species is purified by ion exchange using FPLC (LKB Pharmacia, Inc.). Antisense oligonucleotide analogs are added to either the RNA or DNA complement at stoichiometric concentrations and the absorbance (260 nm) hyperchromicity upon duplex to random coil transition monitored using a Gilford Response II spectrophotometer. These measurements are performed in a buffer of 10 mM Na-phosphate, pH 7.4, 0.1 mM EDTA, and NaCl to yield an ionic strength of either

- 73 -

0.1 M or 1.0 M. Data can be analyzed by a graphic representation of $1/T_m$ vs $\ln[Ct]$, where $[Ct]$ is the total oligonucleotide concentration.

The thermodynamic parameters are determined from this analysis. Based upon the information gained concerning the stability of the duplex of hetero-duplex formed, the placement of modified linkages into oligonucleotide analogs is assessed for their effects on helix stability. Modifications that drastically alter the stability of the hybrid exhibit reductions in the free energy (ΔG) and decisions concerning their usefulness as antisense oligonucleotides are made.

B. Fidelity of hybridization of oligonucleotide analogs

The ability of the antisense oligonucleotide analogs of the invention to hybridize with absolute specificity to a targeted mRNA can be shown by Northern blot analysis of purified target mRNA in the presence of total cellular RNA. Target mRNA is synthesized from a vector containing the cDNA for the target mRNA located downstream from a T7 RNA polymerase promoter. Synthesized mRNA is electrophoresed in an agarose gel and transferred to a suitable support membrane (e.g., nitrocellulose). The support membrane is blocked and probed using [^{32}P]-labeled oligonucleotide analogs. The stringency is determined by replicate blots and washing in either elevated temperatures or decreased ionic strength of the wash buffer. Autoradiography is performed to assess the presence of heteroduplex formation and the autoradiogram quantitated by laser densitometry (LKB Pharmacia, Inc.). The specificity of hybrid formation is determined by isolation of total cellular RNA by standard techniques and its analysis by agarose electrophoresis, membrane transfer and probing with the labelled oligonucleotide analogs. Stringency is predetermined for an unmodified antisense oligonucleotide and the conditions used such that only the specifically

- 74 -

targeted mRNA is capable of forming a heteroduplex with the oligonucleotide analog.

PROCEDURE 2 - Nuclease Resistance

A. Evaluation of the resistance of oligonucleotide analogs to serum and cytoplasmic nucleases.

Oligonucleotide analogs of the invention can be assessed for their resistance to serum nucleases by incubation of the oligonucleotide analog in media containing various concentrations of fetal calf serum or adult human serum. Labeled oligonucleotide analogs are incubated for various times, treated with protease K and then analyzed by gel electrophoresis on 20% polyacrylamide-urea denaturing gels and subsequent autoradiography. Autoradiograms are quantitated by laser densitometry. Based upon the location of the modified linkage and the known length of the oligonucleotide, it is possible to determine the effect on nuclease degradation by the particular modification. For the cytoplasmic nucleases, an HL 60 cell line can be used. A post-mitochondrial supernatant is prepared by differential centrifugation and the labelled oligonucleotide analogs are incubated in this supernatant for various times. Following the incubation, the oligonucleotide analogs are assessed for degradation as outlined above for serum nucleolytic degradation. Autoradiography results are quantitated for comparison of the unmodified and the oligonucleotide analogs of the invention.

B. Evaluation of the resistance of oligonucleotide analogs to specific endo- and exo-nucleases.

Evaluation of the resistance of natural oligonucleotides and oligonucleotide analogs of the invention to specific nucleases (*i.e.*, endonucleases, 3',5'-exo-, and 5',3'-exonucleases) can be done to determine the exact effect of the modified linkage on degradation. The oligonucleotide analogs are incubated in defined reaction buffers specific for various selected

nu
pr
pc
pr
(S
qu
mo
co
cy
PR
As
dis
5-
an
orc
met
ger
dis
tre
als
oth
lys
pre
acc
met
wit
frc
buf
rar
abc
ana
wit

- 75 -

nucleases. Following treatment of the products with protease K, urea is added and analysis on 20% polyacrylamide gels containing urea is performed. Gel products are visualized by staining with Stains All reagent (Sigma Chemical Co.). Laser densitometry is used to quantitate the extent of degradation. The effects of the modified linkage are determined for specific nucleases and compared with the results obtained from the serum and cytoplasmic systems.

10 PROCEDURE 3 - 5-Lipoxygenase Analysis, Therapeutics and Assays

A. Therapeutics

For therapeutic use, an animal suspected of having a disease characterized by excessive or abnormal supply of 5-lipoxygenase is treated by administering oligonucleotide analogs in accordance with this invention. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Such treatment is generally continued until either a cure is effected or a diminution in the diseased state is achieved. Long term treatment is likely for some diseases.

B. Research Reagents

The oligonucleotide analogs of this invention will also be useful as research reagents when used to cleave or otherwise modulate 5-lipoxygenase mRNA in crude cell lysates or in partially purified or wholly purified RNA preparations. This application of the invention is accomplished, for example, by lysing cells by standard methods, optimally extracting the RNA and then treating it with a composition at concentrations ranging, for instance, from about 100 to about 500 ng per 10 mg of total RNA in a buffer consisting, for example, of 50 mM phosphate, pH ranging from about 4-10 at a temperature from about 30° to about 50° C. The cleaved 5-lipoxygenase RNA can be analyzed by agarose gel electrophoresis and hybridization with radiolabeled DNA probes or by other standard methods.

- 76 -

C. Diagnostics

The oligonucleotide analogs of this invention will also be useful in diagnostic applications, particularly for the determination of the expression of specific mRNA species in various tissues or the expression of abnormal or mutant RNA species. In this example, the oligonucleotide analogs target a hypothetical abnormal mRNA by being designed complementary to the abnormal sequence, but would not hybridize to or cleave the normal mRNA.

Tissue samples can be homogenized, and RNA extracted by standard methods. The crude homogenate or extract can be treated for example to effect cleavage of the target RNA. The product can then be hybridized to a solid support which contains a bound oligonucleotide complementary to a region on the 5' side of the cleavage site. Both the normal and abnormal 5' region of the mRNA would bind to the solid support. The 3' region of the abnormal RNA, which is cleaved by the invention compound, would not be bound to the support and therefore would be separated from the normal mRNA.

Targeted mRNA species for modulation relates to 5-lipoxygenase. However, persons of ordinary skill in the art will appreciate that the present invention is not so limited and that it is generally applicable. The inhibition or modulation of production of the enzyme 5-lipoxygenase is expected to have significant therapeutic benefits in the treatment of disease. In order to assess the effectiveness of the compositions, an assay or series of assays is required.

D. In Vitro Assays

The cellular assays for 5-lipoxygenase preferably use the human promyelocytic leukemia cell line HL-60. These cells can be induced to differentiate into either a monocyte like cell or neutrophil like cell by various known agents. Treatment of the cells with 1.3% dimethyl sulfoxide, DMSO, is known to promote differentiation of the cells into neutrophils. It has now been found that basal

- 77 -

HL-60 cells do not synthesize detectable levels of 5-lipoxygenase protein or secrete leukotrienes (a downstream product of 5-lipoxygenase). Differentiation of the cells with DMSO causes an appearance of 5-lipoxygenase protein and leukotriene biosynthesis 48 hours after addition of DMSO. Thus induction of 5-lipoxygenase protein synthesis can be utilized as a test system for analysis of antisense oligonucleotides analogs which interfere with 5-lipoxygenase synthesis in these cells.

A second test system for antisense oligonucleotides makes use of the fact that 5-lipoxygenase is a "suicide" enzyme in that it inactivates itself upon reacting with substrate. Treatment of differentiated HL-60 or other cells expressing 5 lipoxygenase, with 10 μ M A23187, a calcium ionophore, promotes translocation of 5-lipoxygenase from the cytosol to the membrane with subsequent activation of the enzyme. Following activation and several rounds of catalysis, the enzyme becomes catalytically inactive. Thus, treatment of the cells with calcium ionophore inactivates endogenous 5-lipoxygenase. The cells take approximately 24 hours to recover from A23187 treatment as measured by their ability to synthesize leukotriene B₄. Oligonucleotide analogs directed against 5-lipoxygenase can be tested for activity in two HL-60 model systems using the following quantitative assays. The assays are described from the most direct measurement of inhibition of 5-lipoxygenase protein synthesis in intact cells to more downstream events such as measurement of 5-lipoxygenase activity in intact cells.

The most direct effect which oligonucleotide analogs can exert on intact cells and which can be easily be quantitated is specific inhibition of 5-lipoxygenase protein synthesis. To perform this technique, cells can be labelled with ³⁵S-methionine (50 μ Ci/mL) for 2 hours at 37°C to label newly synthesized protein. Cells are extracted to solubilize total cellular proteins and 5-lipoxygenase is immunoprecipitated with 5-lipoxygenase antibody followed by

- 78 -

elution from protein A Sepharose beads. The immunoprecipitated proteins are resolved by SDS-polyacrylamide gel electrophoresis and exposed for autoradiography. The amount of immunoprecipitated 5-lipoxygenase is quantitated by scanning densitometry.

A predicted result from these experiments would be as follows. The amount of 5-lipoxygenase protein immunoprecipitated from control cells would be normalized to 100%. Treatment of the cells with 1 μ M, 10 μ M, and 30 μ M of effective oligonucleotide analogs for 48 hours would reduce immunoprecipitated 5-lipoxygenase by 5%, 25% and 75% of control, respectively.

Measurement of 5-lipoxygenase enzyme activity in cellular homogenates could also be used to quantitate the amount of enzyme present which is capable of synthesizing leukotrienes. A radiometric assay has now been developed for quantitating 5-lipoxygenase enzyme activity in cell homogenates using reverse phase HPLC. Cells are broken by sonication in a buffer containing protease inhibitors and EDTA. The cell homogenate is centrifuged at 10,000 x g for 30 min and the supernatants analyzed for 5-lipoxygenase activity. Cytosolic proteins are incubated with 10 μ M 14 C-arachidonic acid, 2mM ATP, 50 μ M free calcium, 100 μ g/ml phosphatidylcholine, and 50 mM bis-Tris buffer, pH 7.0, for 5 min at 37°C. The reactions are quenched by the addition of an equal volume of acetone and the fatty acids extracted with ethyl acetate. The substrate and reaction products are separated by reverse phase HPLC on a Novapak C18 column (Waters Inc., Millford, MA). Radioactive peaks are detected by a Beckman model 171 radiochromatography detector. The amount of arachidonic acid converted into di-HETE's and mono-HETE's is used as a measure of 5-lipoxygenase activity.

A predicted result for treatment of DMSO differentiated HL-60 cells for 72 hours with effective oligonucleotide analogs at 1 μ M, 10 μ M, and 30 μ M would be as follows. Control cells oxidize 200 pmol arachidonic

- 79 -

acid/ 5 min/ 10^6 cells. Cells treated with 1 μ M, 10 μ M, and 30 μ M of an effective oligonucleotide analogs would oxidize 195 pmol, 140 pmol, and 60 pmol of arachidonic acid/ 5 min/ 10^6 cells respectively.

5 A quantitative competitive enzyme linked immunosorbant assay (ELISA) for the measurement of total 5-lipoxygenase protein in cells has been developed. Human 5-lipoxygenase expressed in *E. coli* and purified by extraction, Q-Sepharose, hydroxyapatite, and reverse phase
10 HPLC is used as a standard and as the primary antigen to coat microtiter plates. A 25 ng portion of purified 5-lipoxygenase is bound to the microtiter plates overnight at 4°C. The wells are blocked for 90 min with 5% goat serum diluted in 20 mM Tris•HCL buffer, pH 7.4, in the presence
15 of 150 mM NaCl (TBS). Cell extracts (0.2% Triton X-100, 12,000 x g for 30 min.) or purified 5-lipoxygenase were incubated with a 1:4000 dilution of 5-lipoxygenase polyclonal antibody in a total volume of 100 μ L in the microtiter wells for 90 min. The antibodies are prepared
20 by immunizing rabbits with purified human recombinant 5-lipoxygenase. The wells are washed with TBS containing 0.05% tween 20 (TBST), then incubated with 100 μ L of a 1:1000 dilution of peroxidase conjugated goat anti-rabbit IgG (Cappel Laboratories, Malvern, PA) for 60 min at 25°C.
25 The wells are washed with TBST and the amount of peroxidase labelled second antibody determined by development with tetramethylbenzidine.

Predicted results from such an assay using a 30 mer oligonucleotide analog at 1 μ M, 10 μ M, and 30 μ M would be
30 30 ng, 18 ng and 5 ng of 5-lipoxygenase per 10^6 cells, respectively with untreated cells containing about 34 ng 5-lipoxygenase.

A net effect of inhibition of 5-lipoxygenase biosynthesis is a diminution in the quantities of
35 leukotrienes released from stimulated cells. DMSO-differentiated HL-60 cells release leukotriene B4 upon stimulation with the calcium ionophore A23187. Leukotriene

- 80 -

B₄ released into the cell medium can be quantitated by radioimmunoassay using commercially available diagnostic kits (New England Nuclear, Boston, MA). Leukotriene B₄ production can be detected in HL-60 cells 48 hours following addition of DMSO to differentiate the cells into a neutrophil-like cell. Cells (2×10^5 cells/mL) will be treated with increasing concentrations of oligonucleotide analogs for 48-72 hours in the presence of 1.3 % DMSO. The cells are washed and resuspended at a concentration of 2×10^6 cell/mL in Dulbecco's phosphate buffered saline containing 1% delipidated bovine serum albumin. Cells are stimulated with $10 \mu\text{M}$ calcium ionophore A23187 for 15 min and the quantity of LTB₄ produced from 5×10^5 cell determined by radioimmunoassay as described by the manufacturer.

Using this assay the following results would likely be obtained with a 15-mer modified linkage bearing antisense oligonucleotide (GCAAGGTCAGTGAAG) directed to the 5-LO mRNA. Cells will be treated for 72 hours with either $1 \mu\text{M}$, $10 \mu\text{M}$ or $30 \mu\text{M}$ oligonucleotide analog in the presence of 1.3% DMSO. The quantity of LTB₄ produced from 5×10^5 cells would be expected to be about 75 pg, 50 pg, and 35 pg, respectively with untreated differentiated cells producing 75 pg LTB₄.

E. In Vivo Assay

Inhibition of the production of 5-lipoxygenase in the mouse can be demonstrated in accordance with the following protocol. Topical application of arachidonic acid results in the rapid production of leukotriene B₄, leukotriene C₄ and prostaglandin E₂ in the skin followed by edema and cellular infiltration. Certain inhibitors of 5-lipoxygenase have been known to exhibit activity in this assay. For the assay, 2 mg of arachidonic acid is applied to a mouse ear with the contralateral ear serving as a control. The polymorphonuclear cell infiltrate is assayed by myeloperoxidase activity in homogenates taken from a biopsy 1 hour following the administration of arachidonic


- 81 -

acid. The edematous response is quantitated by measurement of ear thickness and wet weight of a punch biopsy. Measurement of leukotriene B₄ produced in biopsy specimens is performed as a direct measurement of 5-lipoxygenase activity in the tissue. Oligonucleotide analogs will be applied topically to both ears 12 to 24 hours prior to administration of arachidonic acid to allow optimal activity of the compounds. Both ears are pretreated for 24 hours with either 0.1 μ mol, 0.3 μ mol, or 1.0 μ mol of the oligonucleotide analog prior to challenge with arachidonic acid. Values are expressed as the mean for three animals per concentration. Inhibition of polymorphonuclear cell infiltration for 0.1 μ mol, 0.3 μ mol, and 1 μ mol is expected to be about 10 %, 75 % and 92 % of control activity, respectively. Inhibition of edema is expected to be about 3 %, 58% and 90%, respectively while inhibition of leukotriene B₄ production would be expected to be about 15%, 79% and 99%, respectively.

- 82 -

WHAT IS CLAIMED IS:

1. An oligonucleotide analog in which at least some of the subunits of the analog have the structure:



wherein:

- 5 B_x is a variable base moiety;
 Q is O, CH_2 , CHF or CF_2 ;
 X is H; OH; C_1 to C_{10} lower alkyl, substituted lower
 10 alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN;
 O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ;
 ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl;
 aminoalkylamino; polyalkylamino; substituted silyl; an RNA
 cleaving group; a group for improving the pharmacokinetic
 properties of an oligonucleotide; or a group for improving
 the pharmacodynamic properties of an oligonucleotide;
 15 $L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-$
 CH_2-CH_2 , $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$,
 $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-$
 $NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl,
 substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl,
 20 hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA
 cleaving group, a group for improving the affinity for the
 RNA complement or a group for improving the pharmacodynamic
 25 properties of the oligonucleotide; and

- 83 -

the remaining subunits are natural or synthetic.

2. The oligonucleotide analog of claim 1 wherein Q
is O.

3. The oligonucleotide analog of claim 1 wherein X
5 is H.

4. The oligonucleotide analog of claim 1 wherein X
is OH.

5. The oligonucleotide analog of claim 1 wherein X
is H, OH, F, O-alkyl or O-alkenyl and Q is O.

10 6. The oligonucleotide analog of claim 1 wherein B_x
is adenine, guanine, uracil, thymine, cytosine,
2-aminoadenosine or 5-methylcytosine.

7. The oligonucleotide analog of claim 1
comprising from about 4 to about 50 subunits having said
15 structure.

8. The oligonucleotide analog of claim 1 wherein
substantially all of the subunits have said structure.

9. The oligonucleotide analog of claim 1 wherein
substantially alternating subunits have said structure.


20 10. The oligonucleotide analog of claim 1 wherein
substantially random subunits have said structure.

11. The oligonucleotide analog of claim 1 in a
pharmaceutically acceptable carrier.

25 12. The oligonucleotide analog of claim 1 which
exhibits improved nuclease resistance as compared to
corresponding wild type oligonucleotides.

- 84 -

13. A compound having the structure:



wherein:

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;

5 X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA
10 cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;

$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$,
15 $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA
15 cleaving group, a group for improving affinity for the RNA complement or a group for improving the pharmacodynamic
20 properties of an oligonucleotide comprised of such structures; and

R_{HP1} and R_{HP2} are, independently, H or a hydroxyl
20 protecting group.


25 14. The compound of claim 13 wherein Q is O.

- 85 -

15. The compound of claim 13 wherein X is H.
16. The compound of claim 13 wherein X is OH.
17. The compound of claim 13 wherein X is H, OH, F, O-alkyl or O-alkenyl and Q is O.

5 18. The compound claim 13 wherein B_x is adenine, guanine, uracil, thymine, cytosine, 2-aminoadenosine or 5-methylcytosine.

19. A process for preparing a compound having the structure:



10 wherein:

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;

X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;

15


20

- 86 -


$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where
 5 R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving affinity for the RNA complement or a group for improving the
 10 pharmacodynamic properties of an oligonucleotide comprising the compound; and

R_{HP1} and R_{HP2} are, independently, H or a hydroxyl protecting group;

15 comprising the steps of:
 providing a first synthon having structure (I) and second synthon having structure (II):



(I)



(II)

wherein:

- 20 (a) R_T is NH_2 and R_B is $R_A-CH_2-CH_2$;
 (b) R_T is CH_2-NH_2 and R_B is R_A-CH_2 ;
 (c) R_T is $CH_2-CH_2-NH_2$ and R_B is R_A ;
 (d) R_T is R_A and R_B is $NH_2-CH_2-CH_2$; or
 (e) R_T is CH_2-R_A and R_B is NH_2-CH_2 ;


25 where R_A is $C(O)OH$, $C(S)OH$, or an activated derivative thereof; and

coupling said first synthon and said second synthon to form an amide or thioamide linkage through said R_T and R_B groups.

30 20. A method for modulating the production or activity of a protein in an organism comprising contacting the organism with an oligonucleotide analog specifically

- 87 -

hybridizable with at least a portion of a nucleic acid sequence coding for said protein, wherein at least some of the subunits of the analog have the structure:




wherein:

- 5 B_x is a variable base moiety;
 Q is O, CH_2 , CHF or CF_2 ;
 X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ;
- 10 ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;
- 15 $L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving said oligonucleotide's affinity for the RNA complement or a group for improving the pharmacodynamic properties of the oligonucleotide; and
- 20

the remaining subunits are natural or synthetic.

21. A method for treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligonucleotide analog hybridizable with at least a portion of a nucleic acid sequence coding for said protein, either alone or in a pharmaceutically acceptable carrier, wherein at least some of the subunits of the analog have the structure:



10 wherein:

- B_x is a variable base moiety;
- Q is O, CH_2 , CHF or CF_2 ;
- X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ;
- 15 ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving
- 20 the pharmacodynamic properties of an oligonucleotide; and
- $L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-$

NR-CH₂, and CH₂-C(S)-NR-CH₂ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving the affinity for the RNA complement or a group for improving the pharmacodynamic properties of the oligonucleotide; and

the remaining subunits are natural or synthetic.

rtion
ther
rein

ower

N;

:

;

RNA

tic

ving

and

:(S)-


,

)-

AMENDED CLAIMS

[received by the International Bureau on 3 November 1992 (03.11.92);
original claims 1, 13, 19, 20 and 21 amended; remaining claims unchanged (12 pages)]

1. An oligonucleotide analog in which at least some of the subunits of the analog have the structure:



5 wherein:

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;

X is H; OH; C_1 to C_{10} lower alkyl, substituted lower
alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-
10 , S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH_3 ; SO_2CH_3 ; ONO_2 ;
 NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl;
aminoalkylamino; polyalkylamino; substituted silyl; an RNA
cleaving group; a group for improving the pharmacokinetic
properties of an oligonucleotide; or a group for improving
15 the pharmacodynamic properties of an oligonucleotide;

$\text{L}_1\text{-L}_2\text{-L}_3\text{-L}_4$ is selected from $\text{NR-C(O)-CH}_2\text{-CH}_2$, $\text{NR-C(S)-CH}_2\text{-CH}_2$, $\text{CH}_2\text{-NR-C(O)-CH}_2$, $\text{CH}_2\text{-NR-C(S)-CH}_2$, $\text{CH}_2\text{-CH}_2\text{-NR-C(O)}$, $\text{CH}_2\text{-CH}_2\text{-NR-C(S)}$, $\text{C(O)-NR-CH}_2\text{-CH}_2$, $\text{C(S)-NR-CH}_2\text{-CH}_2$, $\text{CH}_2\text{-C(O)-NR-CH}_2$,
and $\text{CH}_2\text{-C(S)-NR-CH}_2$ where R is hydrogen, alkyl, substituted
20 alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl,

heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving the affinity for the RNA complement, a group for improving the pharmacokinetic properties of an
5 oligonucleotide or a group for improving the pharmacodynamic properties of the oligonucleotide; and

the remaining subunits are natural or synthetic.

2. The oligonucleotide analog of claim 1 wherein
Q is O.

10 3. The oligonucleotide analog of claim 1 wherein
X is H.

4. The oligonucleotide analog of claim 1 wherein
X is OH.

5. The oligonucleotide analog of claim 1 wherein
15 X is H, OH, F, O-alkyl or O-alkenyl and Q is O.

6. The oligonucleotide analog of claim 1 wherein
B_x is adenine, guanine, uracil, thymine, cytosine,
2-aminoadenosine or 5-methylcytosine.

7. The oligonucleotide analog of claim 1
20 comprising from about 4 to about 50 subunits having said
structure.

8. The oligonucleotide analog of claim 1 wherein
substantially all of the subunits have said structure.


9. The oligonucleotide analog of claim 1 wherein
25 substantially alternating subunits have said structure.

10. The oligonucleotide analog of claim 1 wherein
substantially random subunits have said structure.

11. The oligonucleotide analog of claim 1 in a pharmaceutically acceptable carrier.

12. The oligonucleotide analog of claim 1 which exhibits improved nuclease resistance as compared to corresponding wild type oligonucleotides.

13. A compound having the structure:



wherein:

B_x is a variable base moiety;

5 Q is O, CH_2 , CHF or CF_2 ;


X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl;

10 aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;

$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving affinity for the RNA complement, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic properties of an oligonucleotide comprised of such structures; and

20

15. The compound of claim 13 wherein X is H.
16. The compound of claim 13 wherein X is OH.
17. The compound of claim 13 wherein X is H, OH, F, O-alkyl or O-alkenyl and Q is O.
18. The compound claim 13 wherein B_x is adenine, guanine, uracil, thymine, cytosine, 2-aminoadenosine or 5-methylcytosine.
19. A process for preparing a compound having the structure:



wherein:

B_x is a variable base moiety;

Q is O, CH₂, CHF or CF₂;

X is H; OH; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF₃; OCF₃; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group improving the pharmacokinetic properties of an oligonucleotide;


or a group for improving the pharmacodynamic properties of an oligonucleotide;

5 $L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, $CH_2-C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA
10 cleaving group, a group for improving affinity for the RNA complement, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic
15 properties of an oligonucleotide comprising the compound; and

R_{HP1} and R_{HP2} are, independently, H or a hydroxyl protecting group;

comprising the steps of:

20 providing a first synthon having structure (I) and second synthon having structure (II):



wherein:

- 25 (a) R_T is NH_2 and R_B is $R_A-CH_2-CH_2$;
 (b) R_T is CH_2-NH_2 and R_B is R_A-CH_2 ;
 (c) R_T is $CH_2-CH_2-NH_2$ and R_B is R_A ;
 (d) R_T is R_A and R_B is $NH_2-CH_2-CH_2$; or
 (e) R_T is CH_2-R_A and R_B is NH_2-CH_2 ;

30 where R_A is $C(O)OH$, $C(S)OH$, or an activated derivative thereof; and

coupling said first synthon and said second
synthon to form an amide or thioamide linkage through said
NR- R_1 and R_8 groups.

5 20. A method for modulating the production or
activity of a protein in an organism comprising contacting
the organism with an oligonucleotide analog specifically


or

or

oxyl

nd

hybridizable with at least a portion of a nucleic acid sequence coding for said protein, wherein at least some of the subunits of the analog have the structure:



5 wherein:

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;


X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ;
 10 OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an
 15 oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide;

$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-CH_2-CH_2$, $CH_2-NR-C(O)-CH_2$, $CH_2-NR-C(S)-CH_2$, $CH_2-CH_2-NR-C(O)$, $CH_2-CH_2-NR-C(S)$, $C(O)-NR-CH_2-CH_2$, $C(S)-NR-CH_2-CH_2$, CH_2-
 20 $C(O)-NR-CH_2$, and $CH_2-C(S)-NR-CH_2$ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA cleaving group, a group for improving said oligonucleotide's affinity for the

RNA complement, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic properties of the oligonucleotide; and

the remaining subunits are natural or synthetic.

21. A method for treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligonucleotide analog hybridizable with at least a portion of a nucleic acid sequence coding for said protein, either alone or in a pharmaceutically acceptable carrier, wherein at least some of the subunits of the analog have the structure:



wherein:

B_x is a variable base moiety;

Q is O, CH_2 , CHF or CF_2 ;

X is H; OH; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; F; Cl; Br; CN; CF_3 ; OCF_3 ; OCN; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$; SO_2CH_3 ; ONO_2 ; NO_2 ; N_3 ; NH_2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide; and

$L_1-L_2-L_3-L_4$ is selected from $NR-C(O)-CH_2-CH_2$, $NR-C(S)-$

$\text{CH}_2\text{-CH}_2$, $\text{CH}_2\text{-NR-C(O)-CH}_2$, $\text{CH}_2\text{-NR-C(S)-CH}_2$, $\text{CH}_2\text{-CH}_2\text{-NR-C(O)}$,
 $\text{CH}_2\text{-CH}_2\text{-NR-C(S)}$, $\text{C(O)-NR-CH}_2\text{-CH}_2$, $\text{C(S)-NR-CH}_2\text{-CH}_2$, $\text{CH}_2\text{-C(O)}$

-NR-CH₂, and CH₂-C(S)-NR-CH₂ where R is hydrogen, alkyl, substituted alkyl, aralkyl, alkenyl, alkaryl, aminoalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloaralkyl, an RNA 5 cleaving group, a group for improving the affinity for the RNA complement, a group for improving the pharmacokinetic properties of an oligonucleotide or a group for improving the pharmacodynamic properties of the oligonucleotide; and the remaining subunits are natural or synthetic.

STATEMENT UNDER ARTICLE 19 (1)

Claims 1, 13, 19, 20 and 21 have been amended to indicate that R can be a group for improving the pharmacokinetic properties of an oligonucleotide, as stated at, for example, page 9, lines 12-16.

1 / 2




FIG. 1




FIG. 2